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Thao Le Phuong Trinh 
LEPTIN RECEPTOR, A SURFACE MARKER FOR A SUBSET OF HIGHLY 
ENGRAFTING LONG-TERM FUNCTIONAL HEMATOPOIETIC STEM CELLS 
 
The entire hematopoietic system rests upon a group of very rare cells 
called hematopoietic stem cells (HSCs). Due to this extraordinarily crucial role, 
after birth HSCs are localized to the deep bone marrow niche, a hypoxic 
environment inside the bone where HSCs are under well-orchestrated regulation 
by both cellular and humoral factors. Among the cellular components regulating 
hematopoiesis are Leptin Receptor (LEPR)-expressing mesenchymal/stromal 
cells and adipocytes; both have been demonstrated to have significant influence 
on the maintenance of HSCs under homeostasis and in stress-related conditions. 
It has been reported in early work by others that HSCs and hematopoietic 
progenitor cells (HPCs) express LEPR. However, whether LEPR+ HSCs/HPCs 
are functionally different from other HSCs/HPCs was unknown. In this study, I 
demonstrated for the first time that murine LEPR+ Lineage-Sca-1+cKit+ (LSK, a 
heterogenous population consisting of HSCs/HPCs) cells even though 
constituting a small portion of total LSK cells are significantly enriched for both 
phenotypic and functional self-renewing long-term (LT) HSCs as shown in 
primary and secondary transplants in lethally irradiated recipients. LEPR+LSK 
cells are also more enriched for colony-forming progenitor cells assessed by 
colony-forming unit (CFU) assays. In addition, LEPR+ HSCs (defined as 
LSKCD150+CD48-) exhibited robust repopulating potential as compared to LEPR-
ix 
HSCs in long-term competitive transplantation assays. To elucidate the 
molecular pathways that may govern functional properties of LEPR+HSCs, bulk 
RNA-seq on freshly sorted cells was done. Gene set enrichment analyses 
(GSEA) revealed Interferon Type I and Interferon γ (IFNγ) Pathways were 
significantly enriched in LEPR+HSCs while mitochondrial membrane protein gene 
set was significantly enriched in LEPR-HSCs. Interestingly, proinflammatory 
signaling including IFNγ pathway has been suggested to be critical for the 
emergence of embryonic HSCs from the hemogenic endothelium. Altogether, our 
work demonstrated that LEPR+HSCs represent a small subset of highly 
engrafting adult BM HSCs. These results may have potential therapeutic 
implications in the field of hematopoietic transplantation as LEPR is highly 
conserved between mice and humans.  
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CHAPTER ONE: Introduction 
 
1.1 Hematopoietic cell transplantation 
The first hematopoietic cell transplantation (HCT) was performed by Dr. E. 
Donnall Thomas in the late 1950s for a patient with end-stage acute leukemia. It 
was a syngeneic HCT in which the patient received marrow from her identical 
twin after receiving total-body irradiation (Thomas, Lochte, Cannon, Sahler, & 
Ferrebee, 1959). This happened after observational studies that showed 
successful engraftment of bone marrow (BM) cells in myelosuppression (Barnes, 
Corp, Loutit, & Neal, 1956; Lorenz, Uphoff, Reid, & Shelton, 1951). Since then, 
HCT has become an invaluable curative regimen for a variety of diseases 
including malignant and non-malignant conditions (Khaddour, Hana, & 
Mewawalla, 2020).  
 
Allogeneic HCT became more feasible upon the discovery of Human Leukocyte 
Antigens (HLA) in the early 1960s (Dausset, 1958); they are proteins expressed 
on the surface of cells that determine whether donor cells are immunologically 
suitable and compatible for patients. HLA can be divided into two groups. (HLA-
A, B, and C), encoded by the Class I Major Histocompatibility Complex (MHC), 
are expressed by most cell types in the body and are recognized by CD8+ T 
cells. Class II MHC encodes HLA- DP, DQ and DR, which are expressed on 
antigen-presenting cells and recognized by CD4+ T cells. Based on this matching 
system, there are three main types of HCT – autologous transplantation (donor 
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cells are patient’s own cells), syngeneic transplantation (donor cells come from a 
monozygotic twin) and allogenic transplantation (donor cells are from an HLA 
matched family member, an unrelated matched donor or partially mismatched 
family member also called haploidentical) (Khaddour et al., 2020).  
 
Like other types of treatments, HCT has potential complications and can be life-
threatening in some cases. Depending on several factors such as sources of 
transplanted cells, the preparative regimen and age of patients, complications 
can be acute (within 90 days post-transplant) or chronic. Common acute 
complications include insufficient blood cell production (neutropenia, 
thrombocytopenia, anemia), various infections, mucositis and sinusoidal 
obstruction syndrome. Graft-versus-host disease (GVHD) can occur in the acute 
phase or chronically. Other chronic complications include infections with Varicella 
Zoster virus and encapsulated bacteria (Khaddour et al., 2020). 
 
1.1.1 Sources of transplantable cells – advantages and disadvantages 
Successful clinical outcomes of HCT are largely determined by the engraftment 
of rare populations of cells called hematopoietic stem cells (HSCs) and 
hematopoietic progenitor cells (HPCs). In the adult hematopoietic hierarchy, 
HSCs are the only blood cell type that satisfy the definition of adult somatic stem 
cells, which include multipotency (the ability to give rise to all mature blood and 
immune cells) and self-renewal (the ability to generate more HSCs without 
differentiation) (Seita & Weissman, 2010). Meanwhile, multipotent progenitor 
3 
(MPP) cells can differentiate to more mature functional cells but cannot self-
renew. As MPPs differentiate descending the hierarchy, the daughter progenitor 
cells become more and more lineage-restricted. These cells can be collected 
from three main sources – bone marrow (BM), mobilized peripheral blood (mPB) 
and cord blood (CB). Each of these has their own specific advantages and 
disadvantages.  
 
Studies comparing BM vs. mPB HSCs showed that mPB HSCs had a faster 
immune reconstitution rate (Bensinger et al., 2001; Blaise et al., 2000; Powles et 
al., 2000). However, patients who received mPB transplants had higher 
incidences of chronic GVHD (Anasetti et al., 2012; Bensinger et al., 2001) while 
acute GVHD was similar between the two groups in HLA- identical matched 
related donors (Bensinger et al., 2001). Particularly for patients with 
hematological malignancies, most randomized controlled trials comparing 
matched related donor BM and mPB did not find significant differences in terms 
of relapse, transplant-related GVHD and mortality, disease-free survival and 
overall survival (Blaise et al., 2000; Powles et al., 2000). On the other hand, 
compared to both BM and mPB HSCs, CB HSCs (found in a population of CD34+ 
cells) do not require as stringent HLA matching. Cryopreserved CB units are 
more readily available through CB banks, and have less risk of infections as well 
as relatively lower incidences of GVHD, which allows use of partially disparate 
HLA CB units for HCT (Broxmeyer, 2008; Copelan, 2006) . However, this method 
suffers from a delay in engraftment of neutrophils, platelets and immune cell 
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recovery with somewhat higher chances of disease relapses, and the limited 
numbers of HSCs per CB unit is also an issue for larger children and adult 
patients (Broxmeyer, 2008; Khaddour et al., 2020).   
 
1.1.2 Efforts to improve clinical outcomes for patients receiving HCT  
One of the biggest challenges with allogeneic HCT is T-cell immune 
reconstitution, which may take a long time (months to years) and is highly varied 
among patients. As a result, these patients may be at higher risk to develop 
disease relapse or have higher HCT-related morbidity and mortality rate (de 
Koning, Nierkens, & Boelens, 2016).  
 
Several approaches including those for pre-HCT, peri-HCT and post-HCT have 
been taken in order to overcome this problem. For example, a pre-HCT strategy 
is to increase the cell dose transplanted because T-cell recovery needs to be 
preceded by myeloengraftment; hence, a sufficiently high cell number will speed 
up the process. Likewise, the sources of cells also matter – mPB HCT without ex 
vivo T-cell depletion generally has a faster T cell recovery rate compared to BM 
HCT (Ottinger, Beelen, Scheulen, Schaefer, & Grosse-Wilde, 1996; Storek et al., 
2001). During the peri-HCT phase, some studies have suggested that physical 
exercise (Hayes, Rowbottom, Davies, Parker, & Bashford, 2003) and adequate 
specific nutrient supplementations (iron, selenium, zinc and antioxidant vitamins) 
(Cunningham-Rundles, McNeeley, & Moon, 2005; Worthington & Cresci, 2011) 
are important for IR post allogeneic HCT. Several approaches have been 
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investigated to promote T-cell recovery in the post-transplantation period; these 
either target homeostatic peripheral T cell expansion (HPE) or thymopoiesis. IL-2 
cytokine treatment is introduced to induce T cell differentiation and proliferation 
(Inamoto et al., 2011; Kennedy-Nasser et al., 2014); similarly, IL-15 enhances 
HPE by increasing B and T cell expansion (Alpdogan et al., 2005). To promote 
thymopoiesis, treatment with IL-17 increased numbers of functional T cells by 
inducing cell differentiation and proliferation of naïve T cells. It also enhanced T 
cell receptor diversity, which is required for thymopoiesis (Perales et al., 2012). In 
addition, sex steroid ablation (Sutherland et al., 2008), treatments with 
keratinocyte growth factor (Min et al., 2002) or thymosin α1 (Perruccio et al., 
2010) were found to be useful to promote T cell maturation and regeneration.  
 
To quicken the time to hematopoietic recovery, particularly in the case of CB 
HCT, substantial efforts have been made over decades to increase HSC and 
HPC numbers through ex vivo expansion and/or to enhance the ability of 
transplanted cells to home to the BM. The BM is the site where the engrafted 
cells are nurtured for proliferation, survival, self-renewal, and differentiation, and 
since the homing of HSCs is not absolute, the enhancement of having the 
infused cells reach the BM in higher numbers allows for more rapid engraftment 
(Huang, Guo, Capitano, & Broxmeyer, 2019; Huang, Guo, Liu, Wan, & 
Broxmeyer, 2018).  
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Compound screening has yielded numerous exciting results. Small molecules 
such as UM171 (Fares et al., 2014), StemRegenin 1(SR1) (Boitano et al., 2010), 
valproic acid (VPA) (Chaurasia, Gajzer, Schaniel, D'Souza, & Hoffman, 2014) 
were found to expand human HSCs/HPCs several folds. Both SR1 (Wagner et 
al., 2016) and UM171 (Cohen et al., 2020) have been tested in clinical trial phase 
I/II. Notably, neither SR1 or UM171 expanded mouse HSC, so it’s difficult to 
investigate their mechanisms in vivo using murine models. Likewise, treatment 
with recombinant HOXB4 (or its overexpression) induced both human CD34+ and 
mouse HSC expansion (Antonchuk, Sauvageau, & Humphries, 2002; Huang et 
al., 2016; Krosl et al., 2003). One issue with ex vivo experiments is that the 
specific culture conditions matter. Some compounds while being able to expand 
HSCs will not show its effect in certain culture media, like retinoid acid receptor 
(RAR) or peroxisome proliferator-activated receptor (PPAR) gamma antagonists 
when cultured in StemSpanTM Serum-Free Medium (Guo, Huang, Lee, Lee, & 
Broxmeyer, 2018).  
 
For HSCs to migrate and lodge into the BM niche, a key interaction needs to 
occur between CXCR4, a G-protein-coupled chemokine receptor expressed on 
the surface of HSCs, and chemokine ligand CXCL12/stromal cell-derived factor 
(SDF)-1 that is secreted as a gradient to provide HSCs directional cues (Dar et 
al., 2011; C. H. Kim et al., 1999; Lapidot & Kollet, 2002; Q. Ma et al., 1998; 
Sharma, Afrin, Satija, Tripathi, & Gangenahalli, 2011; Zou, Kottmann, Kuroda, 
Taniuchi, & Littman, 1998) . To enhance homing of HSCs to the BM upon 
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transplantation, there have been various strategies, which targets three main 
cellular compartments – cell membrane, cytoplasm and nucleus (Huang et al., 
2019). A very simple and non-invasive approach was to warm the cells for a 
short time (4 hours) that resulted in lipid rafts formation allowing CXCR4 to 
aggregate and hence more likely to interact with CXCL12 (M. L. Capitano, 
Hangoc, Cooper, & Broxmeyer, 2015). The plasma membrane is home to 
different enzymes that can modulate CXCR4-CXCL12 interaction such as 
dipeptidyl peptidase 4 (DPP4). CXCL12 can be truncated by DPP4 and while 
truncated CXCL12 is much less active than full length CXCL12, it strongly blocks 
the activity of full length CXCL12 (Christopherson, Hangoc, & Broxmeyer, 2002) 
interferes with the full-length ligand activity. Hence, inhibition of DPP4 has been 
shown to promote HSC homing and engraftment (Christopherson, Hangoc, 
Mantel, & Broxmeyer, 2004). More recently, nuclear receptor modulators 
including but not limited to gluococorticoid receptor (GR) (Guo, Huang, Cooper, & 
Broxmeyer, 2017; Tan & Wahli, 2016) and histone deacetylase (HDAC) 5 
inhibition (Huang et al., 2018) upregulate CXCR4 expression thereby enhancing 
homing and engraftment of HSCs.  
 
Moreover, it is well-appreciated that HSCs/HPCs are nurtured in a hypoxic BM 
microenvironment (~ 1 5 % oxygen as compared to 21% in ambient air); hence, 
methods for isolation, processing and ex vivo culturing that can protect HSCs 
from the differentiation-inducing effects of hyperoxic reactive oxygen species 
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(ROS) preserve HSC functions and numbers (Huang et al., 2019; Mantel et al., 
2015) 
 
1.2 Overview of murine hematopoiesis 
To meet a tremendous demand of daily blood cell production, millions of mature 
blood cells per day, hematopoiesis needs to be tightly orchestrated over the 
lifetime of an organism (Dzierzak & Medvinsky, 1995; Silva, Anderson, & 
Gatenby, 2011). The entire hematopoietic system relies on a very small number 
of cells namely HSCs. Through a series of more differentiated precursors, HSCs 
give rise to all types of mature blood and immune cells in the body (Rieger & 
Schroeder, 2012). HSCs and HPCs first emerge during embryonic development 
in the yolk sac and the embryonic mesoderm, then migrate to and expand in fetal 
liver, and eventually reside mostly in the adult BM where they interact with a 
complex network of niche cells and noncellular factors (A. L. Medvinsky, 
Samoylina, Muller, & Dzierzak, 1993; Morrison & Scadden, 2014).  
 
HSCs and HPCs are by far the most studied adult stem cells for many reasons – 
they can be physically isolated without significant stress and collected with 
adequate numbers, they can be identified and assessed phenotypically through 
markers, and studied functionally in vitro and in vivo at a single cell level (Rieger 
& Schroeder, 2012). The murine hematopoietic system is arguably the best 
understood system. Early quantitative studies in the field have laid the foundation 
for modern HSC research (Becker, Mc, & Till, 1963; Siminovitch, McCulloch, & 
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Till, 1963; Till, 1961; Till & Mc, 1961). The evolution of different techniques 
allowed studies of lineage tracing (Sun et al., 2014), timing and site specificity of 
cell development and sophisticated functional behaviors in vivo including 
engraftment of human HSCs in immune-compromised humanized mouse models 
(Abarrategi et al., 2018; Bock, Orlic, Dunbar, Broxmeyer, & Bodine, 1995; 
McDermott, Eppert, Lechman, Doedens, & Dick, 2010; Vormoor et al., 1994). 
Excitingly, with the advancement of bioinformatic technology, analyses of large 
datasets have shed light into the molecular, genetic and epigenetic regulations of 
HSCs both in the context of normal and malignant hematopoiesis (Nobile et al., 
2019; Pellin et al., 2019; Zeng et al., 2019).  
 
1.2.1 Emergence of HSCs during embryonic hematopoiesis 
During embryogenesis, the hematopoietic system is derived from the mesoderm, 
which is formed in the primitive-streak-stage at 6.5 days postcoitum (days after 
conception referring to the age of an embryo). Similar to avian and amphibian 
systems, in mouse there are two embryonic sites of hematopoietic activity before 
fetal liver hematopoiesis – the ventral compartments (yolk sac) and the dorsal 
compartments (intraembryonic aorta, genital ridge and mesonephros, also known 
as the AGM region) (Dzierzak & Medvinsky, 1995). It is generally accepted that 
hematopoietic activities in the yolk sac and the AGM happen independently from 
one another (A. Medvinsky, Rybtsov, & Taoudi, 2011). Notably, hematopoietic 
activity in the yolk sac is transient (so called the first wave – primitive 
hematopoiesis) while HSCs and HPCs produced intraembryonically will take 
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residence in definitive hematopoietic organs (also known as the second wave – 
definitive hematopoiesis) (A. Medvinsky et al., 2011).  
 
Blood islands first appear in the extraembryonic yolk sac as early as embryonic 
(E) day 7 (E7) and generate mainly primitive nucleated erythrocytes and to a 
lesser extent granulocytes and macrophages (Godin, Dieterlen-Lievre, & 
Cumano, 1995; Moore & Metcalf, 1970). These are followed with lymphoid 
activity of T and B cells around E8 – 9 (Liu & Auerbach, 1991; Ogawa et al., 
1988) and colony forming units-spleen (CFU-S; more mature subset of HSCs) at 
late E9 (A. L. Medvinsky et al., 1993). Meanwhile, the AGM begins to form at E8 
and gives rise to more potent CFU-S activity than the yolk sac beginning at E9.5 
(A. L. Medvinsky et al., 1993). T and B cells are also found in the paraaortic 
splanchnopleure (P-Sp) in E8 – 9 embryos. Finally, the long-term repopulating 
HSCs arise at late E10 in the AGM (A. L. Medvinsky, Gan, Semenova, & 
Samoylina, 1996; Muller, Medvinsky, Strouboulis, Grosveld, & Dzierzak, 1994). 
Hence, consistent with earlier observations in quail chick chimeric embryos 
(Dieterlen-Lievre, 1975), definitive HSCs (dHSCs) have an intraembryonic origin. 
However, in contrast to avian and similar to human, mouse dHSCs do not 
emerge from blood islands in the region of dorsal aorta but rather intravascular 
region of the aortic hemogenic endothelium and postumbilical arteries (Garcia-
Porrero, Godin, & Dieterlen-Lievre, 1995).  
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There are several evidences that pointed to the crucial role of the AGM region in 
generating definitive adult HSCs autonomously (A. L. Medvinsky et al., 1996). 
Explants from E10.5 and E11.5 AGMs can grow and expand HSCs, respectively 
(Kumaravelu et al., 2002). Similarly, HSCs proliferate in the presence of growth 
factors when cultured with explanted AGMs (Robin et al., 2006; Taoudi et al., 
2008). In transplantation assays, while yolk sac explants only give rise to short-
term erythromyeloid engraftment, E8 para-aortic splanchnopleura explants (prior 
to established circulation) can generate long-term engraftment of lymphomyeloid 
cells (Cumano, Ferraz, Klaine, Di Santo, & Godin, 2001). Moreover, the placenta 
has also been suggested as another site of definitive hematopoiesis. Placenta is 
believed to contain dHSCs concomitantly with the AGM region by E10.5 – 11, as 
shown in transplantation assays (Gekas, Dieterlen-Lievre, Orkin, & Mikkola, 
2005).  
 
Mechanistically, the two key transcriptional regulators of dHSC specification and 
emergence from the AGM are RUNX1 and NOTCH, and they have slightly 
differential roles. Both RUNX1 and NOTCH (also NOTCH targets and ligands) 
are expressed by intra-aortic hemogenic clusters (North et al., 1999; Robert-
Moreno, Espinosa, de la Pompa, & Bigas, 2005). Studies have shown that 
Notch1-/- E9.5 yolk sac and P-Sp cells failed to initiate adult hematopoiesis when 
injected into newborn recipients (Kumano et al., 2003). In parallel, Runx1-/- 
mouse embryos do not develop clonogenic progenitors and dHSCs and die by 
E12.5 even though yolk sac erythropoiesis remains close to normal (Yokomizo et 
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al., 2008).  Unlike Runx1-/- mutants, Notch1-/- embryos have normal clonogenic 
potential in the yolk sac, which suggested that NOTCH1 signaling is specifically 
important for AGM hematopoiesis (Bertrand, Cisson, Stachura, & Traver, 2010). 
In addition, other molecular factors such as bone morphogenetic protein, soluble 
hedgehog, vascular endothelial growth factor as well as nitric oxide signaling and 
shear stress also play a significant role in the induction of hemogenic fate in the 
embryonic AGM (A. Medvinsky et al., 2011).  
 
1.2.2 Definitive (adult) hematopoiesis 
1.2.2.1 Adult HSCs and HPCs 
A few weeks after birth, dHSCs undergo a dramatic phenotypic switch from fetal 
HSCs, which are highly proliferative and engraft robustly with faster kinetics in 
transplantation assays, to adult HSCs, which are mostly quiescent and reside in 
the hypoxic niche of the BM microenvironment (Bowie et al., 2007). Positioned at 
the apex of the hematopoietic hierarchy, HSCs are the only type of blood cells 
that are capable of long-term self-renewal and differentiation into all lineages of 
blood and immune cells. Stepwise identifications using multiple surface markers 
allows isolation of different HSCs and HPCs using fluorescence activated cell 
sorting (FACS). In general, more potent repopulating cells express stem cell 
antigen (Sca-1) and the receptor for stem cell factor (SCF) CD117 (c-Kit) while 
they express low levels of or are negative for mature cell markers (lineage 
markers) (Okada et al., 1992; Spangrude, Heimfeld, & Weissman, 1988). These 
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are called LSK cells, which contain a mixture of different HSC and HPC 
populations.  
 
Based on that foundation, different systems of more refined markers are utilized 
to specifically identify prospective HSCs and multipotent progenitors (MPPs). 
HSCs can be obtained using Mac-1 and CD4 expression levels (HSCs defined 
as LSK Mac-1-CD4-Thy1low and MPPs defined as LSMac-1lowCD4lowThy1low) 
(Morrison, Wandycz, Hemmati, Wright, & Weissman, 1997; Morrison & 
Weissman, 1994). More purified HSCs are also found in LSK cells that are CD34 
negative/low (Osawa, Hanada, Hamada, & Nakauchi, 1996), Flt3 negative 
(Adolfsson et al., 2005; Christensen & Weissman, 2001; L. Yang et al., 2005) or 
have increased efflux of Hoechst dye 33342 (Goodell, Brose, Paradis, Conner, & 
Mulligan, 1996) or low staining for Rhodamine123 dye (Bertoncello, Hodgson, & 
Bradley, 1985). More recently, highly purified functional HSCs and MPPs have 
been identified using the SLAM family markers CD150 (SLAMF1) and CD48 
(SLAMF2) – HSCs are defined as LSKCD150+CD48- and MPPs are defined as 
LSKCD150+CD48- (Forsberg et al., 2005; Kiel et al., 2005; I. Kim, He, Yilmaz, 
Kiel, & Morrison, 2006; O. H. Yilmaz, Kiel, & Morrison, 2006). Notably, SLAM 
HSCs can be further divided into two functionally distinct subsets using Leptin 
Receptor (LEPR) (Trinh et al., 2020). LEPR+SLAM HSCs engrafted more 
robustly than LEPR- cells. In fact, LEPR+ LSK cells contained most HSC activities 
upon transplantation as compared to LEPR- LSK cells.  
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Given the extraordinarily crucial roles that HSCs play in both hematopoiesis and 
immunity, their fate decisions – self-renewal versus differentiation, survival, 
proliferation versus quiescence, mobilization versus homing, lineage choices – 
are constantly under strict regulation. To maintain adequate hematopoietic output 
under homeostasis as well as during stressful conditions, HSCs need to balance 
between self-renewal and differentiation. Uncontrolled differentiation or 
inadequate self-renewal can lead to exhaustion of the HSC pool; in contrast, a 
block in differentiation or abnormally increased self-renewal may result in 
myeloproliferative malignancies. These fate decisions are influenced by both 
extrinsic mechanisms (BM microenvironment) (will be discussed in more details 
in section 1.2.2.2) and intrinsic programs (Rieger & Schroeder, 2012).  
 
For a multipotent cell to commit to a specific cell lineage, there needs to be a 
change in global gene expression – upregulation of that lineage-specific 
programs accompanied by downregulation of genes associated with other 
lineages; this process is orchestrated by activities of different molecular networks 
including transcription factors (TFs), transcriptional cofactors, chromatin 
modifiers and other regulatory factors (Hamey et al., 2017). For example, while 
GATA2 is highly expressed in early progenitors, a switch from GATA2 to GATA1 
mediated by increased interaction between GATA1 and FOG1 and hence 
displacement of GATA2 from its own upstream enhancer initiates erythropoiesis 
(Grass et al., 2003). Furthermore, it has been well-recognized that HSCs are 
comprised of heterogenous populations even at molecular levels (R. Lu, 
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Czechowicz, Seita, Jiang, & Weissman, 2019) with lineage-specific subsets, and 
these lineage biases are influenced by microenvironmental niche factors in the 
BM (Pinho et al., 2018). Similarly, myeloid versus lymphoid biased subsets of 
MPPs have been well-characterized phenotypically and functionally (Pietras et 
al., 2015).  
 
1.2.2.2 Adult bone marrow niches 
Most of the knowledge about BM niches come from studies of mouse long 
bones. BM is a highly dynamic and intricate organ. Proposed by R. Schofield in 
1978, the concept of BM niche refers to the regulatory unit that is required to 
maintain HSC self-renewal and differentiation (Schofield, 1978). BM niches can 
be subdivided into two major categories – the endosteal niche and the vascular 
niche. Understanding how different cellular (hematopoietic and non-
hematopoietic cells) components and growth factors regulate HSC functions can 
have critical implications for the advancements in the field as well as clinical 
applications. 
 
Early studies suggested that HSCs and HPCs are more populated in the 
endosteal region of the bone (Gong, 1978; B. I. Lord, Testa, & Hendry, 1975). In 
addition, upon transplantation into recipients either with (Lo Celso et al., 2009; 
Xie et al., 2009) or without (Nilsson, Johnston, & Coverdale, 2001) 
myeloablation, HSCs tend to home near the endosteal surface. In fact, HSCs can 
be expanded by treating mice with parathyroid hormone, a regulator of bone 
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turnover, mediated partially through enforced Notch signaling (Calvi et al., 2003). 
Furthermore, treatment of mice expressing a truncated form of the herpesvirus 
thymidine kinase gene under the control of rat type I collagen with ganciclovir to 
induce osteoblast ablation reduced the numbers of myeloid, erythroid and 
lymphoid progenitors (Visnjic et al., 2004).  
 
Unlike the early findings, discoveries of SLAM HSC markers and advancement in 
microscopic imaging have revealed that under homeostasis HSCs are localized 
around the sinusoid instead of the endosteum, hence the vascular niche. One of 
the major critical cellular components of the vascular niche are BM-derived 
mesenchymal stem/stromal cells (MSCs), which are capable of self-renewing 
and can potentially differentiate into osteoblasts, adipocytes and chondrocytes 
(B. O. Zhou, Yue, Murphy, Peyer, & Morrison, 2014). Interestingly, both human 
and mouse MSCs when transplanted subcutaneously (Sacchetti et al., 2007) or 
into the renal capsule (Chan et al., 2009) (respectively) of recipient animals form 
an active hematopoietic niche.  
 
MSCs consists of different cell types, and each of them has been demonstrated 
to play a significant role in maintaining hematopoiesis under steady-state and 
some in emergency (stressed) hematopoiesis. One subset of MSCs are 
perivascular Nestin (Nes)+ cells. These cells are closely associated with the 
sympathetic nerves that innervate the BM. Like other tissues in the body, HSCs 
are subjected to circadian rhythm regulation in which they are mobilized into the 
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circulation mediated by actions of the sympathetic nervous system on CXCL12 
expression (Katayama et al., 2006; Mendez-Ferrer, Lucas, Battista, & Frenette, 
2008). Nes+MSCs play an important role in secreting HSC-maintaining factors 
including CXCL12 and SCF. They are also a source of angiopoietin 1 (ANGPT1), 
osteopontin (OPN) and interleukin-7 (IL-7), which is crucial for homeostasis of 
lymphoid progenitors and mature B cells  (Mendez-Ferrer et al., 2010).  Another 
important subpopulation of MSCs are CXCL12-abundant reticular (CAR) stromal 
cells, which are found mostly around sinusoid and secrete SCF as well as IL-7 
(Omatsu et al., 2010). On the other hand, BM adipocytes, also derived from 
MSCs, are suggested to negatively regulate hematopoiesis (Naveiras et al., 
2009). Adipocyte-derived adiponectin inhibits HPC proliferation in vitro (Yokota et 
al., 2000). Upon stress such as post-irradiation adipocytes become abundant and 
enhance HSC recovery by secreting SCF (B. O. Zhou et al., 2017). Among the 
different growth factors, SCF plays an indispensable role in maintaining HSC and 
HPC pools. A mouse model with GFP knock-in at the Scf locus revealed two 
crucial sources of BM SCF, which are endothelial cells (ECs) and LEPR-
expressing stromal cells (Ding, Saunders, Enikolopov, & Morrison, 2012). In 
addition, both of these cell types also secrete pleiotrophin (PTN) that are required 
for HSC homeostasis, while PTN from endothelial cells is critical for the recovery 





1.3 Hematopoiesis during ageing and increased risks for malignancies 
It is well-documented that aging is associated with accumulations of somatic 
mutations ubiquitously present throughout different organs (Hoang et al., 2016; 
Martincorena & Campbell, 2015; Starling, 2018; Welch et al., 2012). These age-
associated mutations can be subdivided into a few major categories; all of them 
have been suggested to happen frequently with ageing. 1) The most prevalent 
one is the spontaneous deamination of 5-methylcytosine to thymine typically on 
CpG dinucleotides (Duncan & Miller, 1980);  2) In DNA double-strand breaks 
nonhomologous end joining occurs as an attempt to fix the damages and may be 
prone to small insertions or deletions (also called indels); 3) Replication errors by 
DNA polymerase can also introduce mismatched base substitutions or indels; 4) 
Larger sized structural variations such as rearrangements or loss of big 
segments of chromosomes.  
 
Under certain selection pressure, some of these mutations may grant HSCs a 
fitness advantage and allow them to outgrow others, creating what is called 
clonal hematopoiesis (CH) (Jaiswal & Ebert, 2019). CH is characterized by the 
overrepresentation of blood cells derived from a single clone regardless of cause 
or disease state. Early evidences of CH came from the observation of TET2 
mutations in approximately 5% of healthy elderly females with nonrandom X-
chromosome inactivation without cancer (Busque et al., 2012). Furthermore, 
patients after being treated for acute myeloid leukemia (AML) were found to 
harbor leukemia-associated AML1/ETO translocation in a subset of normal HSCs 
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and mature blood cells during remission period (Miyamoto, Weissman, & Akashi, 
2000). Subsequent sequencing studies of normal HSC DNA from AML patients in 
remission consistently showed frequent occurrence of single driver mutation that 
possess premalignant potential (Corces-Zimmerman, Hong, Weissman, 
Medeiros, & Majeti, 2014; Jan et al., 2012; Shlush et al., 2014). Remarkably, CH 
arises from mutations in a very small number of genes. In fact, two-thirds of CH 
mutations are found in the two enzyme-encoding genes: DNMT3A and TET2; 
both are involved in DNA methylation. The next most commonly mutated genes 
are ASXL1 and splicing factors (SF3B1, SRSF2, PRPF8, U2AF1) (Jaiswal & 
Ebert, 2019).  
 
To differentiate non-malignant clonal hematopoiesis with cancer-associated 
mutations from other types of clonal hematopoiesis, the term clonal 
hematopoiesis of indeterminate potential (CHIP) was introduced (Steensma et 
al., 2015). In other words, an individual who has cancer-associated mutation in 
their blood cells in the absence of frank malignancy or other clonal entity is 
considered to carry CHIP. In addition, another criterion for CHIP is the threshold 
of variant allele fraction, which is set at 2% (or 4% of cells); this can be lowered 
when other prognostic factors are present (Jaiswal & Ebert, 2019). CHIP is 
particularly significant in myeloid malignancies as mutations frequently found in 
CHIP are also driver mutations of myelodysplastic syndrome (MDS) (Bejar et al., 
2011; Lindsley et al., 2017; Papaemmanuil et al., 2013), myeloproliferative 
disorders (Nangalia et al., 2013), acute myeloid leukemia (AML) (Cancer 
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Genome Atlas Research et al., 2013), and certain lymphoid cancers (Couronne, 
Bastard, & Bernard, 2012). It is of significant clinical implication to point out that 
the size of the mutant clone does matter; the larger the clone, the higher chance 
that it would develop into malignancy (Jaiswal et al., 2014).  
 
Consistent with human studies, genetic models with loss-of-function mutations in 
either Dnmt3a or Tet2 showed HSCs with enhanced competitive repopulating 
potential and being more prone to leukemogenesis in the presence of additional 
mutations (Challen et al., 2011; Ko et al., 2011). In fact, age-associated 
alterations in hematopoiesis in mice have been well-characterized and continue 
to be an intense area of investigation (Broxmeyer et al., 2020; Busque, Buscarlet, 
Mollica, & Levine, 2018; Wahlestedt & Bryder, 2017).  Generally, aged HSCs 
have been demonstrated to exhibit a decline in engraftment (Morrison, Wandycz, 
Akashi, Globerson, & Weissman, 1996) (Rossi et al., 2005) (Sudo, Ema, Morita, 
& Nakauchi, 2000) and homing (Liang, Van Zant, & Szilvassy, 2005) capabilities 
with reduced lymphoid differentiation and concurrently myeloid-biased lineage 
output (Signer, Montecino-Rodriguez, Witte, McLaughlin, & Dorshkind, 2007) 
(Miller & Allman, 2005). It is also observed that there is an expanded number of 
phenotypically-defined HSCs  in aged BM; however, whether their self-renewal 
capacity increases (Rossi et al., 2005) or decreases (Dykstra, Olthof, Schreuder, 
Ritsema, & de Haan, 2011) still needs more investigation.  
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Functional impairments of aged HSCs as compared to young HSCs when 
transplanted into young recipients suggest that the age-associated functional 
defects may be due to cell intrinsic factors. Such autonomous factors have been 
studied including changes in genetic and epigenetic landscapes, altered 
metabolic programs and cell polarity (Broxmeyer et al., 2020; Rossi et al., 2005). 
It is noteworthy to be aware that the collection process under ambient air (as 
most studies have been done) might confound the true characteristics of aged 
HSCs especially in vivo. Previous work has shown that exposure of HSCs to 
ambient oxygen levels within minutes significantly reduced their engrafting 
potential, a process termed extra physiological oxygen stress/shock or EPHOSS 
(Mantel et al., 2015). In fact, isolation and processing of aged HSCs in hypoxic 
conditions restored their functional properties to a significant level (M. L. 
Capitano, Mohamad, S. F., Cooper, S., Guo, B., Huang, X., Gunawan, A.M., 
Sampson, C., Ropa, J., Srour, E.F., Orschell, C.M., & Broxmeyer, H.E., 2020). 
On the other hand, young HSCs transplanted into aged BM showed a reduction 
in engraftment as compared to young BM (Ergen, Boles, & Goodell, 2012; Rossi 
et al., 2005), hence proposing an important role also of extrinsic factors in aged 
hematopoiesis. Interestingly, administration of thrombin-cleaved OPN (its 
secretion by BM stroma normally goes down with age) mitigated some functional 
defects of aged HSCs (Guidi et al., 2017). Notably, there is a shift in bone versus 
fat formation in aged BM MSCs with a tendency toward increasing adiposity; this 
could potentially dampen hematopoiesis (Ambrosi et al., 2017; Singh et al., 2016) 
(Naveiras et al., 2009) as well as promoting the myeloid skewing in lineage 
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output (Adler, Green, Pagnotti, Chan, & Rubin, 2014). With age, the BM 
vasculature is also altered with higher ROS levels, more leaky and lower 
concentrations of HSC supportive factors like CXCL12, SCF, and Jagged1. Co-
culture of aged HSCs with young endothelial cells can restore their repopulating 
potential, whereas co-culture of young HSCs with aged ECs impaired HSC 
function and promoted myeloid bias differentiation (Poulos et al., 2017). Future 
in-depth understanding of the aged BM niche may provide insights for early 
interventions that can potentially rescue or even prevent some of the functional 
impairments of HSCs, which are clinically relevant for both transplantation and 
malignancy fields.  
 
1.4 Leptin and leptin receptor 
1.4.1 Discoveries of leptin/leptin receptor and their roles in non-
hematopoietic systems 
Discovered in the early 1990s as a key regulator of body weight and energy 
expenditure, leptin (LEP) has since been studied extensively in multidisciplinary 
fields (Bahary, Leibel, Joseph, & Friedman, 1990; J. M. Friedman & Halaas, 
1998; J. M. Friedman, Leibel, Siegel, Walsh, & Bahary, 1991; Tartaglia et al., 
1995; Zhang et al., 1994). Different organs are known producers of LEP including 
adipose tissue, placenta, stomach, etc.  Hence, it is not surprising that LEP, a 16-
kDa polypeptide hormone, exerts both central and peripheral effects by binding 
to its receptor (LEPR) (Campfield, Smith, Guisez, Devos, & Burn, 1995; Y. Zhou 
& Rui, 2013). LEPR exists in multiple isoforms as a result of alternative splicing; 
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the long-isoform (Ob-Rb), but not the short isoforms (Ob-Ra, Ob-Rc, Ob-Rd, Ob-
Re), has been demonstrated to fully induce intracellular signaling mostly through 
the JAK/STAT pathway (Gorska et al., 2010; Lee et al., 1996). As a 
neuroendocrine hormone, the effects of LEP on feeding behaviors are mediated 
in part through activation of proopiomelanocortin neurons and inhibition of 
neuropeptide Y/agouti-related protein neurons in the hypothalamus (Cheung, 
Clifton, & Steiner, 1997; Inui, 1999; Smith, Campfield, Moschera, Bailon, & Burn, 
1998; Thornton, Cheung, Clifton, & Steiner, 1997). However, its central effects 
are more intriguingly complex, and involve roles in depression, stress response, 
dopaminergic reward circuits, reproduction and thermoregulation (Barb, 
Hausman, & Lents, 2008; Chou & Mantzoros, 2014; J. Friedman, 2016; J. M. 
Friedman, 2019; Schneider, 2004).  
 
Being secreted mainly by adipocytes in proportion to body fat mass, LEP also 
acts as a proinflammatory adipokine. This is scientifically logical since immune 
functions are well-known to be tightly linked to nutritional status, and LEP is a 
critical messenger of the body energy storage throughout the entire life of an 
individual. It was reported early on that serum LEP levels and Lep mRNA 
expression increases following acute inflammation events or proinflammatory 
cytokine injection (Sarraf et al., 1997). In fact, the roles of LEP and its signaling in 
mature immune cells have been well-investigated. For instance, starvation-
induced immunosuppression and attenuated T-cell immunity were alleviated by 
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treatment with LEP (G. M. Lord et al., 1998). Consistent with this, human LEP 
acted as a negative regulator of regulatory T cells (De Rosa et al., 2007).  
 
1.4.2 Leptin/leptin receptor in hematopoiesis  
1.4.2.1 Leptin/leptin receptor in adult non-malignant hematopoiesis, via 
microenvironmental stromal cells  
In the study of adult hematopoiesis under steady-state conditions, most work has 
focused on the roles of LEPR-expressing stromal cells in the BM niches. This is 
not a great surprise since adipocytes, a potential major source of BM LEP, are 
themselves a critical component of niche cells (Laharrague et al., 1998; Naveiras 
et al., 2009; B. O. Zhou et al., 2017).  It is well-appreciated that HSCs are 
maintained, nurtured and regulated by an intricate and highly dynamic network of 
both cellular and molecular factors (Broxmeyer et al., 2012; Broxmeyer et al., 
2007; Morrison & Scadden, 2014; Sarkaria, Decker, & Ding, 2018; Scadden, 
2014). In order to delineate specific cellular sources of important growth factors 
for HSC homeostasis, a stem cell factor (Scf) green fluorescent protein (Gfp) 
knock-in murine model was employed to elegantly demonstrate that SCF from 
endothelial cells  (ECs) and LEPR-expressing perivascular stromal cells were 
indispensable for BM HSC maintenance. In contrast, deletion of SCF from 
osteoblasts, Nestin-cre- or hematopoietic cells had insignificant effects on the BM 
HSC pool (Ding et al., 2012). Notably, MSCs (including LEPR-expressing stromal 
cells) expressed SCF at higher levels than endothelial cells  (Asada et al., 2017). 
A follow-up study further demonstrated that SCF from endothelial cells was 
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mainly critical for HSCs, whereas SCF from LEPR-expressing stromal cells was 
required not only by HSCs but also by a variety of progenitor cells including 
common lymphoid progenitors, common myeloid progenitors, megakaryocyte-
erythrocyte progenitors and other more differentiated precursor cells 
(Comazzetto et al., 2019).  
 
To elucidate roles of niche cells, including LEPR+ stromal cells, in context of 
hematopoietic recovery post-irradiation, a similar genetic approach as the above 
studies was utilized but to study the specific cellular source of pleiotrophin (PTN) 
rather than SCF in murine BM (Himburg et al., 2018).  At baseline, using Ptn 
floxed/floxed mice (Ptnfl/fl mice) that were crossed with Cre-expressing mice to 
conditionally delete Ptn in different cell types, it was found that under 
homeostasis LEPR+ stromal cells were an indispensable source of PTN required 
for HSC maintenance. In contrast, conditional deletion of Ptn from other cell 
types such as ECs, hematopoietic cells or osteoblasts did not affect HSC content 
nor HSC repopulating function in long-term competitive transplant assays. 
Interestingly, when mice were exposed to a sublethal dose of total body 
irradiation (500 cGy TBI), a shift in the roles of LEPR+ stromal cells versus VE-
cad+ ECs in hematopoietic recovery occurred. Even though Ptn deletion from 
either LEPR+ stromal cells or VE-cad+ ECs resulted in reduction in numbers of 
lin-sca-1+ckit+ (LSK; containing HSCs and progenitors) cells and myeloid 
progenitors by phenotyping analyses, only PTN from VE-cad+ ECs was required 
for recovery of long-term (LT) -HSCs. BM cells from irradiated VE-cad-Cre;Ptnfl/fl 
26 
but not LepR-Cre;Ptnfl/fl mice exhibited reduced repopulating potential in both 
primary and secondary transplants compared to irradiated control mice. 
Secondary transplants allow one to assess the self-renewal capacity of HSCs.  
 
Moreover, altered LEP signaling has been well-documented in obesity (Myers, 
Leibel, Seeley, & Schwartz, 2010). Obesity is a risk factor for hematologic 
malignancies. Patients with obesity have increased mortality rate and HCT- 
associated complications. The indirect involvement of LEP signaling on 
hematopoietic output by modulating BM stromal cells in the context of exercise 
and chronic inflammation such as in atherosclerosis and cardiovascular diseases 
has been reported (Frodermann et al., 2019). Voluntary exercise induced 
HSC/HPC quiescent-promoting niche factors only in LEPR+ stromal cells, but not 
in other niche cellular components, while reducing adipose-tissue-derived LEP 
production. Also, LEP supplementation during exercise increased levels of 
circulating leukocytes, LSK cell proliferation and decreased gene expression of 
BM Angpt1, Cxcl12 and Vcam1 (Frodermann et al., 2019). These findings were 
not mediated through LEP signaling on HSCs/HPCs; effects of exercise 
remained unaffected in wild-type (WT) mice transplanted with LepR-/- BM from 
db/db mice. db/db (or LepR-/-) mice carry a genetic mutation in the Lepr gene that 
causes LEPR inactivation (Bahary et al., 1990). The model is widely used for 
their metabolic phenotypes – obesity, hyperinsulinemia, hyperglycemia, etc. In 
contrast, cell-specific conditional deletion of LepR in stromal cells using Prrx1-
creERT2; Leprfl/fl mice showed a reduction in LSK cell proliferation and circulating 
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leukocytes while enhancing expression of HSC maintenance niche factors 
(Frodermann et al., 2019). This resembled the phenotype in exercising mice. 
Absence of LEP signaling in stromal cells of these mice alleviated the rise in LSK 
cell proliferation and systemic leukocytosis post-myocardial infarction (MI) 
(Frodermann et al., 2019). Treatment with LEP-neutralizing antibody 30 min after 
MI reduced BM colony-forming granulocyte-macrophage progenitor cell 
proliferation and monocytes in the blood and at the site of the infarct. This 
resulted in less inflammation and fibrosis and helped accelerate recovery. Similar 
results were observed in a different model of atherosclerosis (Frodermann et al., 
2019) . These well-designed studies highlighted the significant roles that LEPR-
expressing stromal cells play in both steady-state and emergency hematopoiesis. 
Even though LEP/LEPR involvement in potential various pathological conditions 
in the context of hematopoiesis is only in its infancy, these findings may have 
therapeutic potential in the future.  
 
1.4.2.2 Leptin/leptin receptor in hematopoietic stem and progenitor cells 
Not long after discoveries of LEP and its receptor, a novel sequence was cloned, 
namely B219, which was found in primitive hematopoietic cells isolated from the 
yolk sac, early fetal liver and some lymphohematopoietic cell lines. The 
sequence was expressed in at least four isoforms including one that resembled 
the recently published LEPR;  its amino acid sequence shared similarity with 
granulocyte colony stimulating factor (G-CSF) receptor, gp130 and the leukemia 
inhibitory factor (LIF) receptor (Bahary et al., 1990; Cioffi et al., 1996). In that 
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same year, cloning of different isoforms of LEPR from human hematopoietic cell 
cDNA libraries were reported (Gainsford et al., 1996). Ectopic expression of the 
long isoform OB-Rb in murine Ba/F3 and M1 cell lines respectively induced cell 
proliferation and differentiation. However, it was not clear whether LEP had 
effects on endogenously expressed LEPR and if so, in which hematopoietic cell 
populations. LEP enhanced cytokine production and phagocytosis by murine 
peritoneal macrophage (Gainsford et al., 1996). While these findings were limited 
to in vitro work, they spurred interest in more recent years in the study of LEP 
and its receptor in the field of hematology.  
 
1.4.2.3 Leptin/leptin receptor in hematologic malignancies 
There have been numerous studies in patients with both myeloid and lymphoid 
malignancies that looked at changes in plasma LEP levels during the course of 
the diseases and showed leukemic cells expressing leptin receptor isoforms 
(Gorska, Popko, & Wasik, 2013; Konopleva et al., 1999; Moschovi et al., 2010; 
Mouzaki et al., 2009; Nakao et al., 1998; Ozturk, Avcu, & Ural, 2012; Tsiotra et 
al., 2005; Wasik et al., 2006; Wex et al., 2002; M. Yilmaz et al., 2008). 
Unfortunately, the majority of these publications did not determine whether there 
were any distinct functional properties of LEPR-expressing leukemic cells or if 
LEP signaling played a role in human leukemia pathogenesis and maintenance, 
and if so, how. Still, some of the work provided proof-of-principle evidence of LEP 
and its receptor being possibly involved to some extent in different types of 
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leukemias using patient-derived samples, murine models and human cell, mouse 
recipient xenograft studies.  
 
As early as 1999, using reverse-transcriptase polymerase chain reaction to study 
gene expression levels, it was demonstrated that approximately 50% of collected 
patient specimens of either newly diagnosed primary or secondary acute myeloid 
leukemia (AML) expressed higher levels of the long isoform, than the short 
isoform, of LEPR. This was also true for primary and recurrent acute 
promyelocytic leukemia. In contrast, only the short isoform could be found in 
healthy human promyelocytes (defined as CD34-CD33+ or CD34-CD13+). LEPR 
was not detected in chronic or acute lymphocytic leukemic cells (Konopleva et 
al., 1999). Patient-derived myeloid leukemic blasts and leukemic cell lines 
proliferated at low levels when treated with human recombinant LEP alone and 
significantly at higher levels in the presence of interleukin-3 (IL-3), G-CSF, or 
SCF (Konopleva et al., 1999).  
 
Similarly, another paper characterized in vitro effects of LEP on cultured human 
AML blasts and compared systemic LEP levels in AML patients with healthy 
controls (Bruserud, Huang, Glenjen, Gjertsen, & Foss, 2002).  Serum LEP 
concentrations were significantly lower in untreated AML patients, but were not 
significantly different for patients in remission compared to normal subjects. 
Whether or not this change in serum LEP levels might have been related to the 
treatments was not further investigated. The authors (Bruserud et al., 2002) then 
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looked at in vitro responses of patient-derived AML blasts (mixed CD34+ and 
CD34- leukemic cells) to LEP treatment and found that LEP significantly 
increased blast cell proliferation and secretion of proinflammatory cytokines 
including IL-1β, IL-6, tumor necrosis factor alpha (TNFα) and granulocyte-
macrophage colony-stimulating factor (GM-CSF) in a subset of patients. Notably, 
effects of LEP were observed at supraphysiological levels (2 ug/mL), so it is still 
unclear how these blasts might have behaved differently in response to 
physiological levels of leptin in vivo. Plus, systemic LEP concentrations may 
significantly differ from local sources such as in the leukemic BM niche. This was 
followed up with colony-forming unit assays (used to detect HPCs) using the 
same LEP concentration of 2 ug/mL in two different settings. Specifically, AML 
blasts were cultured for 7 days with or without LEP before being washed and 
plated, or the cells were plated directly in the presence or absence of LEP with 
GM-CSF and Erythropoietin. LEP was found to have minimal effects on colony 
formation, blast differentiation and apoptotic activity. However, results varied 
among patient samples. Overall, while these two studies were of some interest 
and suggested a potential new therapeutic target involving LEPR signaling in 
AML, the scope was limited to in vitro work, and the sizes of patient samples 
were relatively small. Thus, more in-depth future work with rigorous in vivo 
functional assessments and mechanistic insights are warranted. What is known 











• LEPR+ BM MSCs were an indispensable source 
of SCF (Asada et al., 2017; Ding et al., 2012) and 
PTN (Himburg et al., 2018) that were required to 
maintain HSC homeostasis .  
• SCF derived from LEPR+ BM MSCs was critical 
for both HSCs and progenitor cells under steady 
state (Comazzetto et al., 2019). 
• Exercise induced expression of niche factors only 
in LEPR+ BM MSCs while leptin supplementation 




• Isoforms of LEPR were found in both murine and 
human primitive hematopoietic cells (Cioffi et al., 
1996; Trinh T, 2020). 
• Lep signaling through LEPR+ BM MSCs induced 
LSK proliferation and hematopoietic output in 
post-myocardial infarction and atherosclerosis 
(Frodermann et al., 2019).  
• LEPR+LSK cells were highly enriched for 
functional self-renewing LT-HSCs, and 
LEPR+HSCs represented a subset of more 
32 
robustly repopulating LT-HSCs as compared to 





• A significant proportion of patient-derived 
leukemia samples expressed isoforms of Lepr 
(Gorska et al., 2013; Konopleva et al., 1999; 
Mouzaki et al., 2009; Nakao et al., 1998; Ozturk et 
al., 2012; Tsiotra et al., 2005; Wasik et al., 2006; 
Wex et al., 2002).  
• LEP induced myeloid leukemic blasts and cell 
lines to proliferate at low level while enhancing 
effects of IL-3, G-CSF or SCF (Konopleva et al., 
1999).  
• At supraphysiological concentration, LEP 
increased patient-derived AML blast proliferation 
and secretion of IL-6, TNFα, IL-1β and GM-CSF 
(Bruserud et al., 2002).  
• LEPR signaling mediated the anti-leukemic 
protective effects of fasting in B-ALL and T-ALL 
but not AML models by promoting blast cell 
differentiation (Z. Lu et al., 2017).  
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• LEPR+ MSC alterations (e.g. lower expression of 
niche factors, upregulating genes involved in 
fibrosis) played a key role in the pathogenesis of 





















1.4.3 Leptin/leptin receptor in other stem cells 
The therapeutic value of LEP/LEPR in different stem cell-based systems has 
been explored over decades. Here, we describe some of the recent work that 
provided evidence of how LEP and its receptor regulate stem cell functions, with 
some showing potential clinical applications.  
 
Thus far, most of the studies on LEP/LEPR in stem cell biology under 
homeostasis have not fully addressed mechanistically whether and how 
LEP/LEPR directly regulates stem cell functions. It was recently reported using 
mass spectrometry-based global proteomic analyses that LepR-/- (or db/db) 
mouse embryonic fibroblasts had increased levels of phosphorylated ERK1/2, 
RAPTOR and MEK1/2 with the most differentially regulated pathways involving 
mitochondrial dysfunction and oxidative phosphorylation (M. K. Gupta et al., 
2020). Likewise, induced pluripotent stem cells (iPSCs) derived from db/db mice, 
and hence carrying the Lepr mutation, exhibited significant lowered protein levels 
of the pluripotency markers OCT4 and NANOG. db/db iPSCs also revealed a 
proteomic profile that involved pathways regulating mitochondrial functions, 
protein synthesis (including upregulation of eukaryotic translation initiation factor 
4e (EIF4E) and EIF4G) and pluripotency (M. K. Gupta et al., 2020). Molecularly, 
db/db iPSCs were demonstrated to have a reduction in STAT3 phosphorylation 
in response to LEP treatment even though at baseline there was no difference as 
compared to control iPSCs. Chromatin immunoprecipitation analysis revealed 
enrichment of Stat3 binding regions on the promoter of Eif4e of db/db iPSCs, 
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hence leading to enhanced protein synthesis as shown by a higher 
polysome/monosome ratio in polysome profiling study and an increased basal 
oxygen consumption rate in metabolic profiling study. Overall, these findings 
suggest a role(s) of LEP/LEPR both in embryonic stem cell development and in 
regulating pluripotency-associated genes.  
 
In a highly mechanistic study it was demonstrated that production of LEP induced 
by hypoxia preconditioning modulated the level of mitochondrial fusion protein 
OPA1, and hence improved human MSC survival and its therapeutic effects 
under ischemic conditions (F. Yang et al., 2018). While the study showed that 
overexpression of LEP in human MSCs promoted their in vivo therapeutic effects 
including enhanced cardiac function and increased angiogenesis in cardiac 
infarction, it was unclear whether endogenous circulating LEP played any role, 
and if so, would endogenous LEP also act mainly through the 
GSK3/OMA1/OPA1 pathway? In a follow up study (F. Yang et al., 2019), it was 
shown that LEP increased glycolysis in MSCs by upregulating the glucose 
transporter sodium-glucose symporter 1 (SGLT1), and OPA1 was required for 
the effect of leptin on glycolysis. However, it was not well-addressed how OPA1 
could be involved in the enhanced expression of SGLT1 (F. Yang et al., 2019). 
Notably, LEP has been well-known for its angiogenic effect, and was shown to 
increase endothelial cell differentiation from murine embryonic stem cells 
(Kurtovic et al., 2015; Sierra-Honigmann et al., 1998). Furthermore, obese 
patients who have increased risk for cardiovascular diseases may be more likely 
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to have higher systemic LEP levels and LEP resistance. Considering that this 
could also have a negative impact in vivo (Frodermann et al., 2019), it is 
important to weigh potential risks versus benefits as to how the cells may be 
preconditioned before transplantation.  
 
On the other hand, LEP signaling has been studied extensively in context of solid 
tumor cancer stem cells (CSCs), particularly in breast cancer stem cells (BCSCs) 
(Crean-Tate & Reizes, 2018; Lipsey, Harbuzariu, Daley-Brown, & Gonzalez-
Perez, 2016). CSCs represent one of the key challenges to cancer treatments; 
hence, understanding how CSCs are initiated and maintained by the tumor 
microenvironment will have an impact on development of more effective 
therapies. It has been demonstrated that LEPRb maintained stem-cell-like 
characteristics of triple negative breast cancer cells (TNBC) by inducing 
expression of stem cell self-renewal transcription factors OCT4, SOX2 and 
NANOG (Zheng et al., 2013). Using a NANOG promoter-driven GFP activity 
readout, it was observed that mouse LEPR when introduced into human TNBC 
MDA-MB-231 and HCC70 non-CSCs induced NANOG expression (Thiagarajan 
et al., 2017). Two other markers of CSCs SOX2 and OCT4 were also expressed 
at higher levels in LEPR-expressing non-CSCs as compared to control non-
CSCs; this suggested that overexpression of LEPRb was sufficient to convert 
non-CSCs into CSCs. Still, it was not clear whether in situ non-CSCs can 
naturally acquire LEPRb expression to become CSCs and if the transition is 
reversible or not. While LEP signaling can have multiple downstream effectors, 
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the authors showed that LEPRb specifically activated Tyr1077 and Tyr1138 
phosphorylation, which in turn transactivated JAK2/STAT3, a major signaling 
pathway of LEPRb activation.  
 
In a more mechanistic study, it was demonstrated that the pan-JAK inhibitor 
AZD1480 decreased viability of HCC1937 CSCs as compared to its non-CSC 
counterpart and suppressed tumorsphere formation from MCF7 CSCs (T. Wang 
et al., 2018). To understand molecular pathways that governed this 
phenomenon, they performed RNAseq analyses on AZD1480-treated MCF7 
tumorsphere cells and discovered that genes involved in lipid metabolism were 
downregulated (T. Wang et al., 2018). Mechanistically, STAT3 modulated 
expression of genes involved in fatty acid oxidation (FAO) including the rate-
limiting enzyme carnitinepalmitoyl transferase 1 (CPT1), which was required to 
maintain tumor cells in a stem-cell-like state. In line with this, inhibition of STAT3 
in BCSCs reduced their self-renewing capacity. To further explore which 
upstream regulator affects STAT3/FAO pathway in BCSCs, they performed an 
adipokine array using breast adipocyte-conditioned medium. Among the most 
abundantly expressed adipokines was LEP. By using quantitative real time 
polymerase chain reaction and flow cytometry analyses, the only adipokine 
receptor detected at increased levels in the patient-derived BBM2 and BBM3 
tumorsphere cells was LEPR. Consistent with this finding and the fact that LEPR 
signaling is known to activate JAK2/STAT3 pathway, further experiments 
revealed that adding LEP to culture media increased tumorsphere formation, as 
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well as phosphorylation of JAK2 and STAT3. Likewise, treatment with LEP 
neutralizing antibody reversed the increase in expression of CPT1B and ACADM, 
both enzymes involved in the FAO pathway, and reduced the percentage of 
BCSCs in the breast tumors. In fact, in patient tumor samples it was found that 
chemoresistant metastatic breast tumor sections expressed higher level of LEPR 
with LEPR-positive cells having increased CPT1B expression. Altogether, these 
in-depth mechanistic studies using patient-derived samples strongly suggested 
that leptin receptor and its downstream effectors JAK2/STAT3/CPT1 may be 
















CHAPTER TWO: Materials and Methods 
 
2.1 Mice  
2.1.1 Mouse strains  
Female and male Boy/J, B6xBoy/J F1 (herein referred to as F1), and C57BL6/J (8 
– 12 weeks old) were received from the In Vivo Therapeutics Core, an on-site 
breeding core facility at Indiana University School of Medicine. For studies using 
Lep-/- (ob/ob) or Lepr-/- (db/db) mouse models, the mice (male or female) were 
purchased from Jackson Laboratory and acclimated in our animal facility for at 
least one week before the experiment dates. These mice arrived at around 6 – 8 
weeks old and were used at around 2.5 – 3 months old. For all experiments, 
mice were age- and sex-matched. Animals were maintained under light- and 
temperature-controlled conditions (12-hour light/12-hour dark cycle, 21 – 24oC) 
and were housed in groups of 5 maximum per cage according to age, sex, and 
genotype.  
 
2.1.2 Mouse irradiation for transplantations 
F1 recipient mice were irradiated 24 hours prior to transplantation using split 
doses – 700 cGγ followed with 400 cGγ (at least 3 hours apart) in primary 





2.2 Preparation of cells from fresh BM 
Bone marrow were flushed from femurs using ice-cold MACS buffer (PBS 
supplemented with 0.5% BSA and 2 mM EDTA) and dissociated into single cell 
suspension by pipetting with Eppendorf Combitips (Eppendorf). As exceptions, 
for limiting dilution assay of LEPR+LSK and LEPR-LSK cells and RNA-seq 
sample preparation, BM cells were harvested by crushing spines, pelvis, femurs 
and tibias in ice-cold MACS buffer. 
 
2.3 Enrichment of mouse Lin- BM cells and human (h) CB CD34+ cells  
Mouse BM cells were flushed from the femurs (in some cases also tibias and 
pelvis) of C57BL6/J into ice-cold MACS buffer. Mouse BM lineage depletion was 
done following manufacturer’s protocol of the direct mouse lineage cell depletion 
kit (Miltenyi Biotec). Human umbilical CB units were either purchased from Cord 
Use Cord Blood Bank (Orlando, Florida, USA) or obtained as a gift from 
Cleveland CB Bank and used within 24 to 48 hours post-collection. In detail, CB 
was washed in PBS at a volume ratio of 1:1 before Ficoll gradient separation 
using Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB) for mononuclear 
cells. CB CD34+ cells were then isolated using the CD34 MicroBead Kit (Miltenyi 
Biotec) following manufacturer’s protocol.  
 
2.4 Cell staining for flow cytometry analyses and sorting 
For BM analyses at the last time-points of transplants, cells were counted and 
stained at a concentration of 2.5-4 x 106 cells in 200 μl MACS buffer per tube on 
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ice for 20 minutes and washed in PBS. For staining of Lepr HSCs and HPCs, 
cells were first incubated with fluorescently conjugated primary anti-mouse 
antibodies (0.2 μg of antibody was used per one million cells) and anti-LEPR-
biotin antibody (R&D systems, BAF497, 0.2 ug per one million cells), washed in 
PBS, then incubated with secondary streptavidin-PE/Cy7 (Biolegend, Cat.# 
405206) for another 20 minutes on ice (1:500) and washed in PBS. Cells were 
resuspended in diluted DAPI solution (BD Biosciences, 1:10000) before being 
analyzed on a LSR II flow cytometer (BD Biosciences) or sorted using a 
FACSAria or SORP Aria flow cytometers (BD Biosciences). For other HSC and 
HPC staining panels, cells were fixed in 1% paraformaldehyde and analyzed the 
next day.  Data analysis was done using FlowJo 10.7.2 software (BD). Single-
color compensation was included for each experiment; gating strategies were 
determined with fluorescence minus one controls. Percent of each population 
was used to calculate absolute numbers per femur. For human CB phenotyping, 
CD34+-enriched cells were first isolated using the CD34 MicroBead Kit (Miltenyi 
Biotec) following manufacturer’s protocol. Staining procedure was performed in a 
similar fashion to mouse BM cells but with fewer cells per tube (about 200,000 – 
400,000 cells). Full details on the antibodies and clones used for FACS analyses 






Table 2.1 List of fluorophore conjugated antibodies used in the study 
Antibody Fluorophore Clone 
Mouse antibodies 
Mouse lineage cocktail 
(CD3e, CD11b, 
CD45R/B220, Ly-76, Ly-
6G and Ly-6C) 




RB6-8C5 (Ly-6G and Ly-
6C) 
 






Ly6A/E (Sca-1) PE/Dazzle 594 D7 
CD117 (c-Kit) APC/Cyanine 7 2B8 
CD135 (FLT3) APC A2F10 
CD135 (FLT3) PE A2F10 
CD150 PerCP/Cyanine5.5 TC15-12f12.2 
CD150 BV421 Q38-480 
CD48 FITC HM48-1 
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CD34 PE MEC14.7 
CD16/32 PerCP/Cyanine5.5 93 
CD127 BV421 A7R34 
CD45.1 FITC A20 
CD45.2 APC 104 
CD11b PE/Cy7 M1/70 
Ly-6G/Ly-6C (or Gr-1) PE RB6-8C5 
CD3 BV421 17A2 
CD45R/B220 PerCP/Cyanine5.5. RA3-6B2 
Ki67 PE 16A8 
Human antibodies 
CD34 PE 581 
CD38 FITC HIT2 
CD45RA PECF594 HI100 
CD90 Pe-Cy7 5E10 









2.5 Cell cycling assay 
For phenotypic cell cycling studies, freshly isolated BM cells were first partially 
depleted for Lin- cells, stained for surface markers on ice, fixed and permealized 
using BD Fixation/Permealization Solution Kit for 30 min. Then they were stained 
with Ki67 for half an hour at RT (1:20 dilution, 200 uL/million), washed once 
before being stained with DAPI (1:10,000 dilution, 500 ul/million) for 20 min at 
RT. Cells were washed again and resuspended in PBS before being analyzed 
(Galvin et al., 2019; Pietras et al., 2014). 
 
2.6 Colony-forming unit assays 
Freshly sorted cells were plated at 200 cells/ml in 1% methylcellulose culture 
medium supplemented with 30% FBS (Fisher Scientific), 2 mM L-Glutamine 
(Lonza), 0.1 mM hemin (Sigma-Aldrich), 50 ng/ml rmSCF (R&D Systems), 1 U/ml 
recombinant human erythropoietin (rhEPO, Amgen), and 5% vol/vol pokeweed 
mitogen mouse spleen cell conditioned medium. Cells were cultured at 5% CO2, 
5% O2 in a humidified incubator, and colonies were scored on day 6 based on 
morphologies of functional CFU-granulocyte, macrophage (CFU-GM), burst-
forming unit-erythroid (BFU-E), and CFU-granulocyte, erythrocyte, macrophage, 
megakaryocyte (CFU-GEMM) progenitors.  
 
2.6.1 High specific activity tritiated thymidine kill assay 
For high specific activity tritiated thymidine kill assay to determine % CFU in S-
phase of the cell cycle, cells were incubated in IMDM media containing either 
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control diluent or 50 mCi high specific activity tritiated thymidine for 30 minutes in 
the same incubator for cell culture aforementioned before washing and plating. 
For hCB CFU assay, cells were plated in 1% methylcellulose culture medium 
supplemented with 30% FBS, 2 mM L-Glutamine, human recombinant EPO 
(1U/ml), SCF (50 ng/ml), GM-CSF (10 ng/ml) and IL-3 (10 ng/ml) and cultured 
under the same conditions as for mouse cells. Human CFU-GM and CFU-GEMM 
colonies were scored on day 14 after culture, as this combination of growth 
factors does not pick up BFU-E (Broxmeyer et al., 2012; Mantel et al., 2015).  
 
2.7 Competitive transplantation assays to assess engraftment and 
competitive fitness of HSCs 
Freshly sorted LEPR+LSK and LEPR-LSK (or LEPR+HSC and LEPR-HSC) cells 
from pooled BM of donor C57BL6/J (CD45.1-CD45.2+) mice were intravenously 
(i.v.) injected with 100,000 unseparated BM cells of competitor BoyJ 
(CD45.1+CD45.2-) mice into lethally irradiated F1 recipient (CD45.1+CD45.2+) 
mice (n = 5 - 7). At the last time point of primary transplant, marrow from primary 
engrafted mice was pooled within each group and transplanted i.v. into 
secondary recipient (2 x 106 cells per mouse, n = 5 -10) to assess the self-
renewal capacity of the HSCs. Percentages of donor CD45.1-CD45.2+ chimerism 
were determined in the PB at month (mo) 1, 2, 4 (and 5, 6, 7 in some cases) and 
BM at the last time point (Broxmeyer et al., 2012).  
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2.7.1 Limiting dilution assays (LDAs) to calculate numbers of functional 
HSCs 
It is important to note that phenotyping analyses using FACS only allows one to 
assess the numbers of HSCs present but do not provide any information about 
the functions of the cells. Hence, there is a need for LDAs to determine the 
numbers of functional HSCs.  
 
2.7.1.1 Competitive repopulating units (CRUs), measures of mouse BM 
functional HSCs 
Increasing doses of freshly sorted LEPR+LSK and LEPR-LSK cells (50, 100, 150, 
250 cells) or LEPR+HSC and LEPR-HSC (50, 100, 200) from pooled BM of donor 
C57BL6/J (CD45.1-CD45.2+) mice were i.v. injected with 100,000 unseparated 
BM cells of competitor BoyJ (CD45.1+CD45.2-) mice into F1 recipient 
(CD45.1+CD45.2+) mice (n = 5 – 7) that had been lethally irradiated (700 cGγ 
followed with 400 cGγ) 24 hours prior to transplantation. Donor chimerism 
(%CD45.1-CD45.2+) was assessed in PB month 1, 2, 4 (and 5, 6, 7 in some 
experiments) and BM last time point. The number of mice with 1% (for 
LEPR+LSK vs. LEPR-LSK transplant) or 10% (for LEPR+HSCs vs. LEPR-HSCs 
transplant) or greater of donor-derived BM CD45.1-CD45.2+ was determined for 
each dose. The frequency of CRUs was calculated and plotted using ELDA 
software (http://bioinf.wehi.edu.au/software/elda/) (M. L. Capitano et al., 2019).  
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2.7.1.2 SCID-repopulating cells (SRCs), measures of human CB functional 
HSCs 
For hCB LDA transplant, different doses (1000, 2500, 5000) of freshly sorted 
total CD34+, LEPR+CD34+ or LEPR-CD34+ cells were i.v. transplanted into young 
adult NSG mouse recipients (n = 5) that had been sublethally-irradiated (350 
cGγ) 24 hours prior to injection. Human CD45+ chimerism was determined at 
month 2, 4 in PB and month 4 in BM. The number of mice with 0.2% or greater of 
hCD45+ chimerism was assessed for each dose. The frequency of SRCs was 
calculated and plotted using ELDA software 
(http://bioinf.wehi.edu.au/software/elda/) (Chen et al., 2019; Mantel et al., 2015). 
 
2.8 Homing assay  
HSCs do not home to the BM after infusion into mice with absolute efficiency, 
hence the need to assess the homing efficiency of cells injected. Freshly sorted 
LEPR+LSK and LEPR-LSK cells (7000 cells) from pooled BM of donor C57BL6/J 
(CD45.1-CD45.2+) mice were i.v. injected into lethally irradiated (700 cGγ 
followed with 400 cGγ, 24 hours prior to transplantation) BoyJ recipient 
(CD45.1+CD45.2-) mice. Seventeen hours post-injection, BM from host mice was 
harvested and analyzed by flow cytometry to determine the numbers of CD45.1-





2.9 Bulk RNA-sequencing 
2.9.1 Preparation of cells for RNA extraction 
Mouse BM cells were collected by crushing spines, pelvis, femurs and tibias from 
two young adult C57BL6/J mice into ice cold MACS buffer. Single cells were 
staining and sorted fresh on the same day. LEPR+ or LEPR- HSCs or MPPs 
were sorted directly into lysis buffer containing 2-betamercapthanol.  
 
2.9.2 Library preparation, data collection and analyses  
RNA was extracted right after sorting and subjected to library prep using Takara 
Smart-Seq V4 Ultra Low Input RNA kit. Libraries were sequenced using an 
Illumina NovaSeq 6000. Reads were trimmed by Cutadapt, and FastQC was 
used to check the quality of reads. Reads were then aligned and assigned to 
genes using STAR aligner and HTSeq feature counter. Differential gene 
expression analyses were performed using DESeq2.  Gene set enrichment 
analyses were performed using the R package ‘fgsea’.  
 
2.10 Statistical analyses  
Results are expressed as mean values ± SD. A p value less than 0.05 was 
considered statistically significant. Mann-Whitney test or unpaired two-tailed 
Student’s t test was used where indicated. Ordinary one-way ANOVA with post- 
hoc Tukey’s multiple-comparisons test was used when comparing 3 or more 
groups. Ordinary two-way ANOVA with post-hoc Tukey’s multiple-comparison 
test was used when comparing groups of two different categorical variables. For 
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limiting dilution assay transplants, Poisson statistical analysis was used. 























CHAPTER THREE: LEP/LEPR signaling is not required for HSC/HPC 
maintenance under homeostasis, but LEPR-expressing HSCs represent a 
subset of highly engrafting long-term functional hematopoietic stem cells 
 
3.1 LEPR+ cells are significantly outnumbered by LEPR- cells in young 
adult C57BL6/J WT mouse BM  
Early studies by others suggested that leptin enhanced HPC colony formation 
(Bennett et al., 1996; Cioffi et al., 1996; Claycombe, King, & Fraker, 2008; 
Gainsford et al., 1996; Umemoto et al., 1997). Furthermore, LEPR+ stromal cells 
have been well-characterized as a critical component of BM niche cells for their 
role in the secretion of growth factors (GFs) to support HSCs and HPCs under 
steady-state and in regenerative conditions (Comazzetto et al., 2019; Ding et al., 
2012; Himburg et al., 2018; B. O. Zhou et al., 2017; B. O. Zhou et al., 2014). 
Even though it was observed that hematopoietic cells only expressed the 
truncated short isoforms of Lepr (B. O. Zhou et al., 2014), I questioned whether 
germ-line knockout of Lep or Lepr might have an indirect effect on hematopoiesis 
since LEP/LEPR played such an important role in BM stromal cells. Towards this 
aim, I performed extensive phenotypic analyses on BM freshly collected from 
either WT mice or from Lep-/- or Lepr-/- mice.  
 
To confirm expression of LEPR on hematopoietic cells and determine 
percentages of LEPR-expressing cells among various HSC and HPC 
populations, flow cytometry analyses were utilized. I found that the majority of 
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HSCs/HPCs did not express Lepr, consistent with reports that only 0.3% of BM 
cells are LEPR+ cells (B. O. Zhou et al., 2014). Results were similar regardless of 
which marker panels was used. Using the CD34 and FLT3 markers, I found that 
LT-HSC (defined as LSKCD34-Flt3-) contained a significantly higher fraction of 
LEPR+ cells compared to different progenitor populations including Common 
Myeloid Progenitor (CMP, defined as LKFcgRintCD34+), Granulocyte-
Macrophage Progenitor (GMP, defined as LKFcgRhiCD34+), Megakaryocyte-
Erythroid Progenitor (MEP, defined as LKFcgR-CD34+/-) and Common Lymphoid 
Progenitor (CLP, defined as Lin-Sca-1lowcKitlowFlt3+IL7R+) (Figure 3.1Ai) 
(Doulatov, Notta, Laurenti, & Dick, 2012).  
 
On the other hand, using the SLAM marker system with CD150 and CD48 as 
well as FLT3, it was found that  the percentage of LEPR+ cells in the long-term 
SLAM HSC (Lin-Sca-1+c-Kit+Flt3-CD150+CD48-) (LSK Flt3-CD150+CD48-, 
hereafter denoted as SLAM-HSCLT) population was significantly higher than that 
of short-term (ST) SLAM HSC (LSK Flt3-CD150-CD48- or SLAM-HSCST) and 
different subsets of lineage-biased MPPs including the myeloid-biased MPP2 
(LSK Flt3-CD150+CD48+), the myeloid-biased MPP3 (LSK Flt3-CD150-CD48+), 
and the lymphoid-biased MPP4 (LSK Flt3+CD150-CD48+) (Figure 3.1Aii) (Pietras 

















































Figure 3.1_ BM LEPR+ cells are significantly outnumbered by LEPR- cells 
FACS analyses of freshly isolated BM cells from young adult C57BL/6J mice 
(n=8-10).  
(Ai). Percentages of LEPR+ versus LEPR- cells (using the CD34 and FLT3 
markers) within each population (LT-HSC, ST-HSC, MPP, CMP, GMP, MEP, 
CLP). 
(Aii). Percentages of LEPR+ versus LEPR- cells (using the SLAM markers CD150 
and CD48 as well FLT3) within each population (SLAM-HSCLT, SLAM-HSCST, 
MPP2, MPP3, MPP4).  
 
All data are mean ±SD. # p<0.0001 using Mann-Whitney test comparing LEPR+ 
versus LEPR-  cells within each population in (Ai) and (Aii), * p<0.05, ** p<0.01, 
*** p<0.001, **** p<0.0001 using Ordinary One-way ANOVA followed with post-
hoc Tukey’s multiple comparison test to compare fractions of LEPR+ among 
different populations to SLAM-HSCLT in (Ai) or LT-HSC in (Aii). N = 2 









3.2 Germline Knockout of murine Lep or Lepr did not alter numbers of BM 
phenotypic HSCs/HPCs under homeostasis 
To determine whether LEP/LEPR signaling is important for hematopoiesis under 
steady-state conditions, I performed phenotypic studies using flushed BM from 
either WT or Lep-/- or Lepr-/- mice. FACS analyses of BM collected from Lep-/- or 
Lepr-/- in comparison to WT mice revealed no significant differences in total BM 
cellularity (Figure 3.2A), absolute numbers of LT-HSC (Figure 3.2B), ST-HSC 
(Figure 3.2C), MPP (Figure 3.2D), CMP (Figure 3.2E), MEP (Figure 3.2G) and 
CLP (Figure 3.2H). Notably, there was a significant increase in the number of 
GMP in Lepr-/- as compared to WT (Figure 3.2F). This suggested that LEP/LEPR 
axis does not have any roles (direct or indirect) on the maintenance of HSC/HPC 
populations at least in non-stressed situations. Perhaps, it was true that the 
isoforms of Lepr expressed by hematopoietic cells were only the truncated non-



























Figure 3.2_Germline Knockout of murine Lep or Lepr did not alter numbers 
of BM phenotypic HSCs/HPCs. 
Freshly isolated BM from femurs of Lepr-/- or Lep-/- or wild-type (WT) control were 
used for FACS phenotyping analyses.  
(A) Total cellularity per femur.  
(B) Absolute cell numbers of LT-HSCs per femur.  
(C) Absolute cell numbers of ST-HSCs per femur.  
(D) Absolute cell numbers of MPP per femur.  
(E) Absolute cell numbers of CMP per femur.  
(F) Absolute cell numbers of GMP per femur.  
(G) Absolute cell numbers of MEP per femur.  
(H) Absolute cell numbers of CLP per femur.  
 
All data are mean ± STD. Unpaired Student’s t-test was performed. * p < 0.05, ** 
p < 0.01, *** p < 0.001 compared with WT control.   
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3.3 LEPR+LSK cells were more highly enriched for phenotypically defined 
HSCs and MPPs and contained significantly higher numbers of HPCs as 
compared to LEPR-LSK cells 
As discussed in chapter one, HCT is a curative treatment for many hematological 
and non-hematological disorders. Unfortunately, due to their rarity the limited 
number of HSCs remains as one of the most significant obstacles for 
advancements in the field. Further complicating this issue is the fact that 
phenotypic markers used to identify these cells do not always align with their 
functional properties upon transplantation (Chen et al., 2019). Therefore, the 
search for a functional marker for HSCs is clinically relevant and crucial.  
 
The data presented in section 3.2 suggested that LEP/LEPR signaling is not 
required to maintain HSC/HPC pool in murine BM under steady state. However, 
from a clinical standpoint I am interested in how LEPR-expressing HSCs might 
behave differently from the LEPR-negative HSCs during the reconstitution 
process. Here, I sought to determine whether LEPR-expressing HSCs/HPCs 
were functionally different from their negative counterparts particularly during 
stressful events such as post-irradiation.  
 
To determine the proportions of SLAM-HSC (LSKCD150+CD48-, hereafter 
denoted as HSC) and SLAM-MPP (LSKCD150-CD48-,  hereafter denoted as 
MPP) populations that were contained within each compartment ( LEPR+LSK 
versus LEPR-LSK), I used the gating strategy described in Figure 3.3Ai, and 
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found that LEPR+LSK cells were highly enriched for both phenotypically-defined 
HSCs and MPPs (Figure 3.3Aii). This finding suggested that if LEPR can be used 
as a reliable marker for functional HSCs and HPCs in vitro as well as in vivo, 
then LEPR+ LSK should give rise to more colonies in colony forming unit (CFU) 













































Figure 3.3 LEPR+LSK cells were more highly enriched for phenotypically 
defined HSCs as compared to LEPR-LSK cells.  
FACS analyses of freshly isolated BM cells from young adult C57BL/6J mice 
(n=8-10).  
(Ai). Representative gating strategy to determine fractions of SLAM-HSC 
(LSKCD48-CD150+) and SLAM-MPP (LSKCD48-CD150-) within each population 
(LEPR+LSK vs. LEPR-LSK).  
(Aii). Fractions of SLAM-HSC and SLAM-MPP cells within each population 
(LEPR+LSK vs. LEPR-LSK).  
 
All data are mean ±SD. * p<0.05, *** p<0.001 using Mann-Whitney test to 
compare fractions of SLAM-HSC, SLAM-MPP in (Aii) out of LEPR+ LSK vs. 












3.4 Compared to LEPR-LSK cells, LEPR+LSK cells contained significantly 
higher numbers of both colony-forming progenitor cells and functional 
long-term self-renewing HSCs 
Compared to LEPR-LSK cells, LEPR+LSK cells were significantly enriched for 
phenotypically identified HSCs and MPPs. Hence, I hypothesized that LEPR+LSK 
cells might outperform LEPR- cells in engraftment studies and/or yield more 
colonies in CFU assay.  
 
Potential differences in differentiation capacity of LEPR+LSK cells with LEPR-LSK 
cells were assessed using CFU assays. I sorted each population from freshly 
isolated young adult C57BL/6J BM and plated them in equal numbers (200 – 300 
cells/dish). As predicted, LEPR+LSK cells produced significantly higher absolute 
numbers of functional CFU-granulocyte, macrophage (CFU-GM), burst-forming 
unit-erythroid (BFU-E), and CFU-granulocyte, erythrocyte, macrophage, 




























Figure 3.4 Compared to LEPR-LSK cells, LEPR+LSK cells contained 
significantly higher numbers of colony-forming progenitor cells. 
Equal numbers of freshly sorted LEPR+LSK vs. LEPR-LSK cells from C57BL/6J 
femur BM were plated in triplicate for each mouse in CFU assay.   
(A). Absolute numbers of CFU-GM per dish. 
(B). Absolute numbers of BFU-E per dish. 
(C). Absolute numbers of CFU-GEMM per dish. 
 
Data are mean ± SD of  5 mice per group plated in triplicate; N = 2 
(independently repeated experiments). Student’s t test was used. * p<0.05, ** 















More importantly, to evaluate the engraftment functions of HSCs contained within 
each population - LEPR+LSK vs. LEPR-LSK cells, I performed long-term 
competitive transplantation assay in which equal numbers of freshly sorted 
LEPR+LSK and LEPR-LSK cells (1000 cells/recipient) from young adult 
C57BL/6J donor BM (CD45.1-CD45.2+) were mixed with young adult BoyJ 
competitor BM cells (CD45.1+CD45.2-) and intravenously (i.v.) injected into 
lethally irradiated F1 (CD45.1+CD45.2+) mice. Like the CFU results, LEPR+LSK 
cells engrafted more robustly as evaluated by donor CD45.2+ chimerism in the 
peripheral blood (PB) at month 1, 2, 4, 6, 7 as well as in the BM at month 7 
(Figure 3.5A). An independently repeated transplant showed similar results 
(Figure 3.5B).  
 
To further confirm that mice received LEPR+LSK BM cells had better donor 
engraftment as a result of having more functional HSCs and HPCs using 
phenotyping analyses, I collected BM from the F1 mouse femurs and analyzed 
for different phenotypic stem/progenitor populations. Consistently, LEPR+LSK 
cells had higher absolute numbers of donor CD45.2+ LSK, MEP, CMP and GMP 
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Figure 3.5 Compared to LEPR-LSK cells, LEPR+LSK cells were highly 
enriched for functional long-term HSCs. 
Equal numbers of freshly sorted LEPR+LSK vs. LEPR-LSK cells from C57BL/6J 
femur BM were used in competitive transplant assays (n=5 recipients/group). For 
the primary transplants, BM was pooled from 5 donor mice before sorting.   
(A). Percentages of CD45.2+ donor chimerism in PB month 1,2,4,6,7 and BM 
month 7 respectively.  
(B). Percentages of CD45.2+ donor chimerism in PB month 2,4,6 and BM month 
6 respectively. 
(C-F). Absolute numbers per femur of donor LSK, MEP, CMP and GMP in the 
BM of primary F1 recipient mice at month 7 respectively. 
 
Data are mean ±SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 using 










Competitive repopulating units, CRUs, are a functional measure of mouse HSC 
numbers. To determine actual numbers of functional HSCs, a limiting dilution 
engraftment assay (LDA) was done. Frequency of CRUs was found to be 
significantly much higher in LEPR+LSK than in LEPR-LSK cells (Figure 3.6A, B). 
In the limiting dilution transplant, LEPR+LSK cells consistently engrafted better 
than LEPR-LSK as demonstrated by higher CD45.2+ donor chimerisms in PB 
throughout month 1, 2, 4 and BM month 4 (Figure 3.6Ci-iv respectively). In line 
with this, FACS analysis of recipient mouse BM at the last time point showed that 
LEPR+LSK group contained significantly higher absolute numbers of donor LSK 
and MEP cells (Figure 3.6Di-ii respectively) with a trend towards higher numbers 


































































Figure 3.6 LEPR+LSK cells contained significantly higher numbers of 
competitive repopulating units (CRUs) as compared to LEPR-LSK cells in a 
limiting dilution assay transplant.  
Freshly isolated different doses of donor cells from C57BL6/J (CD45.2+) 
combined with 100,000 competitor cells from BoyJ (CD45.1+) were i.v. injected 
into F1 recipients. Engraftment data from month 4 BM was used to calculated 
CRUs using a cut off value of 1%.  
(A). Poisson statistical analysis from the limiting dilution analysis. Solid lines 
represent the best-fit linear model for each data set. Dotted lines represent 95% 
confidence intervals.  Symbols represent the percentage of negative mice for 
each dose of cells. Plot was modified from the original for better clarity.  
(B). No. of CRUs per one million transplanted cells calculated from (A). Line 
indicates median.  
(Ci-iv). Percentages of CD45.2+ donor chimerism in PB month 1,2,4 and BM 
month 4 respectively.  
(Di-iv). Absolute numbers per femur of donor LSK, MEP, CMP and GMP in the 
BM of primary F1 recipient mice at month 4 respectively. 
 
Data are mean ±SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 using 





Self-renewal is one of the hallmark characteristics of functional long-term HSCs. 
To assess the ability of self-renewing of LEPR+HSCs as compared to LEPR-
HSCs, at the last time-point of each primary transplant, I collected BM from the 
F1 recipient mice and transplanted them into lethally irradiated secondary hosts. 
Consistent with primary transplant results, LEPR+LSK cells engrafted much more 
extensively than LEPR-LSK cells in the PB throughout month 1, 2, 4, 5 and BM 
month 5 of the secondary transplant (Figure 3.7A). The same trends were 
observed in secondary transplants of an independently repeated experiment 




























































Figure 3.7 Compared to LEPR-LSK cells, LEPR+LSK cells were more highly  
 
enriched for self-renewing HSCs as shown in secondary transplants.  
 
Whole BM flushed from primary F1 recipients were pooled within each group and 
i.v. injected into secondary recipients (n=10 recipients).  
(A). Percentages of CD45.2+ donor chimerism in secondary mice in the PB 
month 1, 2, 4, 5 and BM month 5. 
(B) Percentages of CD45.2+ donor chimerism in secondary mice in the PB month 
1, 2, 4 and BM month 4 of an independently repeated experiment. 
 
Data are mean ±SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 using 














3.5 LEPR differentiates SLAM HSCs into two functionally distinct 
populations with LEPR+HSCs, a smaller subset but with significantly higher 
repopulating potential  
Members of the SLAM family markers, CD150 and CD48, are arguably the most 
widely used markers for long-term functional HSCs (Oguro, Ding, & Morrison, 
2013). To elucidate whether LEPR can functionally classify SLAM HSC 
(LSKCD150+CD48-) into two distinct subpopulations, I performed a competitive 
limiting dilution transplantation assay in which three different doses of freshly 
sorted LEPR+HSC or LEPR-HSC cells from young adult C57BL6/J donor BM 
(CD45.1-CD45.2+) combined with unseparated young adult BoyJ competitor cells 
(CD45.1+CD45.2-) were i.v. injected into lethally irradiated F1 mice 
(CD45.1+CD45.2+). Interestingly, LEPR+HSCs possessed superior engrafting 
capability as compared to LEPR-HSCs as shown by statistically significantly 
higher donor CD45.2+ chimerism in the PB at month 1, 2, 4 and BM month 4 
(Figure 3.8Ai-iv respectively).  In fact, using Poisson statistical analysis I found 
that LEPR+HSCs were significantly enriched for CRUs as compared to LEPR-
































































Figure 3.8 LEPR differentiates SLAM HSCs into two functionally distinct 
populations with LEPR+HSCs, a smaller subset but with significantly higher 
repopulating potential.  
Different doses of LEPR+HSCs and LEPR-HSCs were sorted from freshly 
isolated and pooled BM cells from C57BL/6J femurs (n=15 mice) and used in a 
limiting dilution assay transplant (n=7 recipients/group).  
(Ai-iv). Percentages of CD45.2+ donor chimerism in PB month 1, 2, 4 and BM 
month 4 respectively.  
(B). Poisson statistical analysis from the limiting dilution analysis. Solid lines 
represent the best-fit linear model for each data set. Dotted lines represent 95% 
confidence intervals.  Symbols represent the percentage of negative mice for 
each dose of cells. Plot was modified from the original for better clarity.  
(C). No. of CRUs per one million transplanted cells calculated from (B). Line 
indicates median.  
 
Data are mean ±SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 using 
Ordinary One-way ANOVA followed with post-hoc Tukey’s multiple comparison 








In addition, FACS analysis of BM month 4 confirmed that mice received 
LEPR+HSCs contained significantly higher numbers of donor LT-HSC, MPP, 
MEP, CMP and GMP (Figure 3.9A, C-F respectively) and a trend towards higher 































































Figure 3.9 BM from recipient mice transplanted with LEPR+HSCs were  
 
significantly  enriched with HSCs and HPCs. 
 
Different doses of LEPR+HSCs and LEPR-HSCs were sorted from freshly 
isolated and pooled BM cells from C57BL/6J femurs (n=15 mice) and used in a 
limiting dilution assay transplant (n=7 recipients). FACS analyses of recipient BM 
at month 4.  
(A - F) Absolute cell numbers of LT-HSCs, ST-HSCs, MPP, MEP, CMP, and 
GMP per femur respectively. 
 
Data are mean ±SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 using 














3.6 LEPR+HSCs did not exhibit a lineage bias in competitive transplantation 
assays, shared similar homing capacity and cycling status with LEPR-HSCs  
The pleiotrophic effects of leptin functions of mature immune cells both of the 
myeloid and lymphoid branches have been well-recognized (Naylor & Petri, 
2016). To determine whether LEPR+HSCs have any biases in lineage fate 
decision, I analyzed the percentages of donor B220+ B cells, CD3e+ T cells and 
CD11b+ myeloid cells in both PB and BM at the last time points of primary 
transplants. Compared to the LEPR-HSCs, LEPR+HSC donor cells had similar 
percentages of B220+ B cells, CD3e+ T cells and CD11b+ myeloid cells in PB and 
BM month 4 in all three doses of a limiting dilution assay (Figure 3.10Ai-iii).  The 
same trend was observed in two other transplants (Figure 3.10B, C). Hence, we 
concluded that LEPR+HSCs had a similar lineage output with LEPR-HSCs and 












































Figure 3.10 LEPR+HSCs had a similar lineage output with LEPR-HSCs.  
(Ai-iii) Three different doses of freshly sorted LEPR+HSC vs. LEPR-HSC cells 
were used in a limiting dilution assay transplant. Percentages of donor B220+ B, 
CD3e+ T and CD11b+ myeloid cells in primary F1 hosts in PB month 4 and BM 
month 4 in three doses.  
(B) Equal numbers of freshly sorted LEPR+LSK vs. LEPR-LSK cells were used in 
a regular straight-up transplant assay. Percentages of donor B220+ B, CD3e+ T 
and CD11b+ myeloid cells in primary F1 hosts in PB month 5, 6 and BM month 6. 
N = 2 
(C). Different doses of freshly sorted LEPR+LSK vs. LEPR-LSK cells were used 
in a limiting dilution assay transplant. Percentages of donor B220+ B, CD3e+ T 
and CD11b+ myeloid cells in primary F1 hosts in PB month 4 and BM month 4.  
 
Data are mean ±SD. Ordinary One-way ANOVA followed with post-hoc Tukey’s 










Upon being injected into the hosts, HSCs need to migrate to and lodge into the 
BM niche for engraftment to happen. During this process, expression of CXCR4 
by HSCs allow the cells to sense and follow the CXCL12 (or SDF1) chemotaxic 
gradient by the BM niche cells. This early phase of engraftment is termed 
‘homing,’ and increase in homing could be one factor that contributed to 
enhanced repopulating outcome. As a result, since enhanced engraftment could 
be due to increased numbers of cells homed to the BM, I performed a homing 
assay by i.v. injecting equal numbers of freshly sorted LEPR+LSK and LEPR-LSK 
cells from young adult C57BL6/J donor BM (CD45.1-CD45.2+) into lethally 
irradiated BoyJ (CD45.1+CD45.2-) hosts. Seventeen hours later, BM was flushed 
from the recipient femurs and stained for FACS analyses. LEPR+LSK and LEPR-
LSK cells were found to home at similar capacities, as shown by similar numbers 
of homed LK, LSK and LSKCD150+ cells (Figure 3.11Ai-iii respectively). In line 
with this, there was no significant difference in CXCR4 surface staining between 
LEPR+HSC, LEPR+MPP as compared to LEPR-HSC and LEPR-MPP cells 










































Figure 3.11 LEPR+HSCs homed to the BM niche at a similar capacity and 
shared similar levels of CXCR4 expression with LEPR-HSCs. 
(Ai-iii) Equal numbers (7000 cells) of freshly sorted BM LEPR+LSK and LEPR-
LSK were i.v. injected into lethally irradiated BoyJ recipient mice. BM was flushed 
from their femurs and immunophenotypically analyzed 17 hours post-injection. 
Absolute numbers of donor CD45.2+ LK, LSK and LSKCD150+ cells were 
determined.  
(Bi) Surface staining (or mean fluorescence intensity) of CXCR4 on LEPR+HSC 
and LEPR-HSC.  
(Bii) Histograms of level of expression of surface CXCR4 on LEPR+HSC, 
LEPR+MPP as compared to LEPR-HSC, and LEPR-MPP. 
 
Data are mean ±SD. Ordinary One-way ANOVA followed with post-hoc Tukey’s 











Being protected in a hypoxic microenvironment, it is widely accepted that long-
term HSCs are mostly quiescent and rarely divide to avoid replicating exhaustion 
and uncontrolled differentiation due to exposure to the harmful ROS. Hence, I 
determined the cycling status of LEPR+HSCs/MPP cells as compared to LEPR-
HSCs/MPP cells by using phenotypic FACS studies. In addition, I also studied 
the cycling characteristics of more mature progenitor cells through using 
radioactive high specific activity tritiated thymidine in CFU assay. Both LEPR+ 
functional CFU-GM progenitor cells (assessed by high specific activity tritiated 
thymidine kill CFU assay) (Figure 3.12A) and LEPR+HSCs and LEPR+MPPs 
(assessed by phenotype) had similar percentages of cells in cycle compared to 



















































Figure 3.12 LEPR+HSCs shared similar cycling status with LEPR-HSCs. 
(A) Equal numbers of freshly sorted BM LEPR+LSK and LEPR-LSK from each 
mouse (n = 5 mice) were plated in triplicate in a high specific activity tritiated 
thymidine kill CFU assay. Percentages of CFU-GM progenitor cells in cycle for 
each population.  
(Bi-ii) Percentages of cells in different phases of the cell cycle for LEPR+HSCs 
(or LEPR+MPP) vs. LEPR-HSCs (or LEPR-MPP). N = 2 (independently repeated 
experiments).  
 















3.7 LEPR+HSCs constitute a subset of functional long-term repopulating 
HSCs that is characterized by a pro-inflammatory transcriptomic signature 
To delineate the potential transcriptomic networks that modulate the functional 
differences between LEPR+HSC/MPP and LEPR-HSC/MPP cells, I sorted fresh 
BM cells for each population and used them for bulk RNA-sequencing.  
 
Using a non-biased data-driven approach, heatmap analysis showed a total of 
564 genes expressed at higher levels and 511 genes expressed at lower levels 
in LEPR+HSC compared to LEPR-HSC (Figure 3.13 A). We also found that 
LEPR+MPP contained 409 genes more highly expressed and 130 genes less 
expressed compared to LEPR-MPP (Figure 3.13C, D). Interestingly, LEPR+HSC 
cells expressed at higher levels genes involved in megakaryocytopoiesis such as 
Mpig6b, Plekhb1, and Tubb1.  In addition, log2(fold change) of expression level 
analysis showed that LEPR+HSCs more highly expressed genes encoding 
cytoskeleton and structural/matrix proteins (Cdc42ep1, Lnx1, Fbln5, Nid1), as 
well as genes related to cell proliferation, differentiation, adhesion and motility 
(Lrg1, Hoxb7, Chrdl1, Sema4f) (Figure 3.13B). Notably, both LEPR+HSC and 
LEPR+MPP cells expressed significantly higher levels of LEPR as an internal 



























This was done with help from Dr. James Ropa. 
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Figure 3.13 LEPR+HSCs/MPPs are transcriptomically distinctive from LEPR-
HSCs/MPPs.  
LEPR+HSCs/MPPs and LEPR-HSCs/MPPs were sorted from freshly isolated BM 
from C57BL6/J directly into 2-β mercaptoethanol-supplemented lysis buffer and 
subjected to bulk RNA-sequencing (n=5 biological replicates/population). A 
positive enrichment score indicates the gene program is enriched in LEPR+ cells 
and vice versa.  
(A, C). Bland-Altman plots (MA plot) showed fold changes of genes in 
LEPR+HSCs/LEPR-HSCs in (A) (or LEPR+MPPs/LEPR-MPPs in (C)) versus the 
average expression of those genes in all samples. Red represented genes that 
are significantly expressed at higher level in LEPR+HSCs/MPPs; blue 
represented genes that are significantly expressed at lower level in LEPR-
HSCs/MPPs.  
(B). Heatmap representation of the top 100 more highly expressed genes in 
LEPR+HSCs than LEPR-HSCs; genes discussed in the text are listed to the right 
of the heatmap. The data is calculated by row. Light-blue color indicates lower 
row z-score; dark-blue color indicates higher row z-score. 
 (D). Heatmap representation of the top 50 more highly expressed genes in 
LEPR+MPPs than LEPR-MPPs, which are listed to the right of the heatmap. The 
data is calculated by row. Light-blue color indicates lower row z-score; dark-blue 





To further determine which isoform(s) were expressed, we performed additional 
quantitative analyses by dividing exons into counting bins using unique 
annotated transcripts and reads being assigned to exon bins. Results showed 
LEPR+HSC/MPP expressed predominantly the short isoforms Lepr-a (or Ob-Ra) 
and Lepr-c (or Ob-Rc) but not the long isoform Lepr-b (or Ob-Rb), which was 
essentially undetectable (Figure 3.14A, B). This suggested that the LEPR 
expressed by these cells might not be capable of fully transducing intracellular 
signaling at least under steady state conditions as when the cells were collected 







































This was done with help from Dr. James Ropa. 
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Figure 3.14 LEPR+HSC/MPP expressed predominantly the short isoforms 
Lepr-a and Lepr-c but not the long isoform Lepr-b.  
(A). Normalized RNA-seq tracks demonstrate that there are many reads mapped 
to the Lepr exon 19 associated with Lepr isoform a, and very few mapped to the 
Lepr exon 19 associated with Lepr isoform b in murine HSCs and MPPs.  
(B). RNA-seq was reanalyzed by dividing exons into counting bins using unique 
annotated transcripts, and reads were assigned to exon bins. Exon bin 28, which 
contains Lepr exon 19 that is included in the Lepr transcript that codes isoform a 
is highly represented in the RNA-seq, while Lepr exon 19 that is included in the 















To further gain insight into the molecular pathways that characterized each cell 
population, we performed gene set analysis by fast gene set enrichment analysis 
(FGSEA). The results revealed that LEPR+HSCs were enriched for Type-I 
Interferon and Interferon-gamma (IFN-γ) response pathways, whereas LEPR-
HSCs were enriched for genes involved in mitochondrial membrane protein and 
respiratory electron transport chain with Normalized Enrichment Scores of 2 or 
higher (Figure 3.15A, Ci-ii respectively). LEPR-MPP cells were enriched for DNA 
replication genes, while LEPR+MPP cells were enriched for extracellular matrix 
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Figure 3.15 LEPR+HSCs were characterized by proinflammatory 
transcriptomic pathways, whereas LEPR-HSCs were enriched for genes 
involved in mitochondrial membrane protein and respiratory electron 
transport chain. 
LEPR+HSCs/MPPs and LEPR-HSCs/MPPs were sorted from freshly isolated BM 
from C57BL6/J directly into 2-β mercaptoethanol-supplemented lysis buffer and 
subjected to bulk RNA-sequencing (n=5 biological replicates/population). A 
positive enrichment score indicates the gene program is enriched in LEPR+ cells 
and vice versa.  
(A). Gene set analysis showed enriched gene sets of molecular functions and 
biological processes in LEPR+HSCs using the R package “FGSEA” 
(B). Gene set analysis showed enriched gene sets of molecular functions and 
biological processes in LEPR+MPPs using the R package “FGSEA” 











In addition, the top more highly expressed candidates in LEPR+HSCs gene 
expression profile were enriched with genes involved in pro-inflammatory 
immune responses and regulatory processes including Relb and Rel, which 
encode subunits of the NF-κB complex (Figure 3.13B). This was particularly 
intriguing because both IFN-γ and NF-κB signaling pathways are characterized 
as being critical for HSC emergence in the aorta-gonad-mesonephros (AGM) 
during embryonic development (Espin-Palazon et al., 2014; Espin-Palazon & 
Traver, 2016; Sawamiphak, Kontarakis, & Stainier, 2014; Zhao et al., 2012). It 
has been demonstrated by others that deletion of NF-kB subunit p65/RelA led to 
impairments in HSC long-term engraftment (Stein & Baldwin, 2013). In fact, 
further gene set analyses showed that LEPR+HSCs were enriched for genes 
associated with long-term HSCs, whereas LEPR-HSCs were enriched for an 































 This was done with help from Dr. James Ropa. 
100 
Figure 3.16 LEPR+HSCs were enriched for genes associated with long-term 
HSCs, whereas LEPR-HSCs were enriched for an intermediate progenitor 
gene profile. 
LEPR+HSCs/MPPs and LEPR-HSCs/MPPs were sorted from freshly isolated BM 
from C57BL6/J directly into 2-β mercaptoethanol-supplemented lysis buffer and 
subjected to bulk RNA-sequencing (n=5 biological replicates/population). A 
positive enrichment score indicates the gene program is enriched in LEPR+ cells 
and vice versa.  
(A-B). Additional FGSEA plots for gene sets associated with LT-HSC and 















3.8 Human CB (hCB) LEPR+CD34+ cells, a minor subset of total CD34+ cells, 
were more highly enriched for phenotypically defined HSCs and showed a 
trend to enhanced engraftment compared to LEPR-CD34+ cells in NSG mice 
Using FACS analyses, hCB CD34+ cells can be subdivided into CD34dim (CD34d) 
and CD34bright (CD34bri). Interestingly most CD34bri were LEPR-expressing cells, 
which formed a distinct smaller subset out of the total CD34+ cell population 
(Figure 3.17A). To determine fractions of human phenotypic HSCs (pHSCs) and 
MPPs (pMPPs) within each population (LEPR+CD34+ vs. LEPR-CD34+), I used a 
gating strategy as shown in Figure 3.17A.  Consistent with mouse data for 
LEPR+LSK vs. LEPR-LSK cells, hCB LEPR+CD34+ cells contained significantly 
higher fractions of human phenotypically identified HSCs (defined as 
CD34+CD38-CD45RA-CD90+) (Figure 3.17Bi), but a lower fraction of MPPs 

































pHSC: CD34+CD38-CD45RA-CD90+                  pMPP: CD34+CD38-CD45RA-CD90- 
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Figure 3.17 Human CB (hCB) LEPR+CD34+ cells, a minor subset of total 
CD34+ cells, were more highly enriched for phenotypically defined HSCs.  
Using FACS analysis, freshly enriched hCB CD34+ cells were phenotyped for 
LEPR expression in human HSCs (defined as CD34+CD38-CD45RA-CD90+) and 
MPPs (defined as CD34+CD38-CD45RA-CD90-).  
(A). Representative gating strategy to determine fractions of human 
phenotypically identified HSCs and MPPs within each population 
(LEPR+CD34+vs. LEPR-CD34+)  
(Bi-ii). Fractions of human pHSCs (Bi) and pMPP (Bii) within each population 
(LEPR+CD34+vs. LEPR-CD34+ respectively) (N = 5) 
 
Data are mean ±SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 using 












To compare the differentiation potential of subsets of CD34+ cells in vitro, I plated 
equal numbers of freshly sorted LEPR+CD34bri, LEPR+CD34d and LEPR-CD34d 
in a CFU assay. Numbers of colonies were determined after 14 days in culture. 
Interestingly, LEPR+CD34bri cells had the lowest absolute numbers of both CFU-
GM and CFU-GEMM colony-forming cells in comparison to the other two groups. 
There were no significant differences between LEPR+CD34d and LEPR-CD34d 
groups (Figure 3.18Ai-ii).  
 
To assess the engrafting potential of LEPR+CD34+ as compared to LEPR-CD34+ 
cells, we performed a limiting dilution assay in which equal numbers of each 
population were sorted from freshly isolated hCB CD34+-enriched cells and i.v. 
injected into sublethally-irradiated immune deficient NOD/SCID IL-2 receptor 
gamma chain null (NSG) mice. SCID-repopulating cells (SRCs) were calculated 
using Poisson statistical analysis (Figure 3.18Bi). LEPR+CD34+ cells were 
enriched with a 2.9 fold difference of SRCs compared to LEPR-CD34+ cells in the 
highest dose (p = 0.1; Figure 3.18Bii). Consistent with the mouse data, using 
percentages of human CD3+ T cells, CD19+ B cells and CD33+ myeloid cells the 
myeloid/lymphoid ratio of engrafted CD34+ cells calculated was similar in all 





























Figure 3.18 hCB LEPR+CD34+ cells showed a trend to enhanced 
engraftment compared to LEPR-CD34+ cells in NSG mice. 
 (Ai-ii). Freshly sorted hCB LEPR+CD34bri, LEPR+CD34dim and LEPR-CD34dim 
cells were assessed for colony formation capacity in CFU assay. 
Absolute numbers of CFU-GM (Ai) and CFU-GEMM (Aii) colonies scored 14 
days after plating equal numbers of LEPR+CD34bri, LEPR+CD34dim and LEPR-
CD34dim in semisolid methylcellulose supplemented with GFs and cytokines. (N = 
2 independently repeated experiments) 
(Bi). Different doses (1000, 2500, 5000) of freshly sorted total CD34+, 
LEPR+CD34+ or LEPR-CD34+ cells were i.v. injected at equal numbers into 
sublethally irradiated immunocompromised NSG mice in a limiting dilution assay. 
Poisson statistical analysis from the limiting dilution analysis. Solid lines 
represent the best-fit linear model for each data set. Dotted lines represent 95% 
confidence intervals.  Symbols represent the percentage of negative mice for 
each dose of cells. Plot was modified from the original for better clarity.  
(Bii). # of SRCs per one million injected cells calculated from (Bi) Line indicate 
median.  
(C). Myeloid/lymphoid ratio was calculated using percentages of human CD33+ 
myeloid, CD3+ T and CD19+ B cells with no statistical differences.  
Data are mean ±SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 using 
Ordinary One-way ANOVA followed with post-hoc Tukey’s multiple comparison 
test in (Ai-ii, C). Poisson statistical analysis in (Bi) p = 0.1.  
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3.9 Phenotypic characterizations of LEPR+ hematopoietic stem and 
progenitor cells in middle-aged mice as compared to LEPR- cells 
The metabolic activities of a cell are adaptively regulated by systemic signals that 
reflect the nutritional status of an organism throughout its life (Shapira & 
Christofk, 2020; Y. P. Wang & Lei, 2018). This is particularly crucial in the case of 
HSCs as they are rare, and they have to maintain the integrity of an entire organ 
system. One way that the body communicates nutritional cues to HSCs is via 
systemic hormonal regulations. Indeed, various metabolic hormones have been 
well-documented to influence hematopoiesis, and aging can significantly alter 
these metabolic messengers hence indirectly affects HSC functional behaviors 
(Stewart et al., 2014; Xia et al., 2015; Zhang et al., 2017). 
 
As an adipokine, leptin is recognized to have a broad spectrum effects on 
numbers and functions of different immune cells under homeostasis (La Cava & 
Matarese, 2004). Aging is known to be associated with multiple immune 
dysregulations including declined adaptive immune responses (Ongradi & 
Kovesdi, 2010). Recently, leptin has been demonstrated to induce gene 
expression of p16, a marker of cellular immunosenescence in human B cells 
from young lean adults.  These cells also exhibited lowered class switching 
activity and ability to produce influenza-specific IgG (Frasca & Blomberg, 2017; 
Frasca, Diaz, Romero, & Blomberg, 2020). Unfortunately, the study was limited 
to in vitro treatment only and did not provide full mechanistic insights. In line with 
this finding, Gupta et al. demonstrated that leptin induced significantly higher 
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levels of IL-10, TNF-α, and IL6 from aged human B cells as compared to young 
controls, and this effect was mediated through the STAT3 signaling pathway 
downstream of leptin receptor activation (S. Gupta, Agrawal, & Gollapudi, 2013). 
Another group reported that sustainably higher leptin levels were found in LPS-
treated old (24 month) rats compared to young (2 month) animals, and the old 
rats showed delayed but longer febrile response. Elevated leptin concentrations 
were accompanied by increased levels of pro-inflammatory cytokines including 
IL-6 and IL-1Rα; however, it was not determined whether the increase in leptin 
level was causative and how (Koenig et al., 2014). Although leptin signaling was 
consistently reported to be altered in aged animals, more rigorously designed 
studies are needed to help us understand how this well-known proinflammatory 
neuroendocrine adipokine may play any roles in aging-associated immunological 
changes (Filippi & Lam, 2014; Gabriely, Ma, Yang, Rossetti, & Barzilai, 2002).  
 
In addition, it has been demonstrated that BM adipose tissue possessed brown 
fat properties that declined in old or diabetic mice (Krings et al., 2012). 
Interestingly, Ambrosi et al. demonstrated that during the process of aging or in 
obesity MSCs preferentially differentiated into adipocytes, which impaired 
hematopoietic recovery (Ambrosi et al., 2017) . Since BM adipocytes could be a 
potential source of leptin, it is important to know how BM adipocyte-derived leptin 
can indirectly alter hematopoiesis as the animal ages.  Given that LEPR (OB-R) 
was also reported to be expressed by different types of both myeloid and 
lymphoid leukemic cells (Z. Lu et al., 2017; Nakao et al., 1998; Ozturk et al., 
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2012; Wex et al., 2002), it will be intriguing and important to determine whether 
aging has a differential selection pressure on LEPR+HSCs as compared to the 
rest of total BM HSCs particularly in the context of clonal hematopoiesis.  
 
To assess how LEPR-expressing HSC and HPC populations may alter 
differentially from LEPR- cells with aging, I first performed FACS phenotypic 
analyses (Figure 3.19). Interestingly, results revealed that fractions of the more 
immature populations such as long-term HSCs (LT-HSC defined as LSKFLT3-
CD34-) (Figure 3.20Ai), short-term HSCs (ST-HSC defined as LSKFLT3-CD34+) 
(Figure 3.20Aii, ), and multipotent progenitor (MPP defined as LSKFLT3+CD34+) 
(Figure 3.21A) expanded significantly with aging as fractions of LEPR- cells 
reduced. Consistent with this, fractions of long-term SLAM HSCs (SLAM HSCLT 
defined as LSKFLT3-CD150+CD48-) (Figure 3.20Bi), the lymphoid-biased MPP4 
(LSKFLT3+CD150-CD48+) (Figure 3.21Bi), the myeloid-biased MPP2 (LSKFLT3-
CD150+CD48+) (Figure 3.21Bii), and MPP3 (LSKFLT3-CD150-CD48-) (Figure 
3.21Biii), all significantly increased as the mice aged. However, short-term SLAM 
HSCs (SLAM HSCST defined as LSKFLT3-CD150-CD48-) remained similar in 
proportions as compared to LEPR- cells in young vs. older mice (Figure 3.20Bii). 
On the same line, the more mature LEPR-expressing progenitor populations 
including CMP, GMP and MEP remained significantly lower in proportions 
compared to LEPR- cells in young vs. middle-aged mice (Figure 3.22A-C 
respectively).  Altogether, the data suggested that aging affected LEPR-
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expressing stem and more immature multipotent progenitor cell groups to a 






















Figure 3.19 Representative plots of HSCs in middle-aged mice in 


























































































































Figure 3.20 With age, fractions of long-term LEPR+ SLAM HSCs expanded 
over LEPR- SLAM HSCs 
Freshly isolated BM from either young adult or middle-aged C57BL6/J mice (n = 
8-10/group) were immunophenotypically analyzed for long-term and short-term 
HSCs. 
(Ai-ii). Percentages of LEPR+ SLAM HSCLT and LEPR+ SLAM HSCST as 
compared to LEPR- cells in young vs. middle-aged mice. 
(B) Percentages of LEPR+ LT-HSC and LEPR+ ST-HSC as compared to LEPR- 
cells in young vs. middle-aged mice. 
 
Data are mean ±SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 using 
Ordinary Two-way ANOVA followed with post-hoc Tukey’s multiple comparison 

















































































































Figure 3.21 With age, fractions of total MPP and different lineage-biased 
MPP subsets expanded over LEPR- populations.  
Freshly isolated BM from either young adult or middle-aged C57BL6/J mice (n = 
8-10/group) were immunophenotypically analyzed for total and lineage-biased 
MPP subsets. 
(A). Percentages of LEPR+ total MPP as compared to LEPR- cells in young vs. 
middle-aged mice. 
(B) Percentages of LEPR+ MPP2, MPP3, and MPP4 as compared to LEPR- cells 
in young vs. middle-aged mice. 
 
Data are mean ±SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 using 
Ordinary Two-way ANOVA followed with post-hoc Tukey’s multiple comparison 





























































































Figure 3.22 Unlike stem cells, LEPR+ progenitor populations did not expand 
with aging and remained as low as in young BM.  
Freshly isolated BM from either young adult or middle-aged C57BL6/J mice (n = 
8-10/group) were immunophenotypically analyzed LEPR and lineage-specific 
progenitor cells. 
(A). Percentages of LEPR+ CMP as compared to LEPR- cells in young vs. 
middle-aged mice. 
(B) Percentages of LEPR+ GMP as compared to LEPR- cells in young vs. middle-
aged mice. 
(B) Percentages of LEPR+ MEP as compared to LEPR- cells in young vs. middle-
aged mice. 
 
Data are mean ±SD. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 using 
Ordinary Two-way ANOVA followed with post-hoc Tukey’s multiple comparison 










CHAPTER FOUR: DISCUSSION AND FUTURE DIRECTIONS 
 
4.1 Discussion  
HCT is widely used to treat, and in certain cases to cure patients with 
hematologic malignancies or other blood and immune disorders. Each method of 
HCT has its own advantages and disadvantages as aforementioned. 
Remarkably, CB transplantation has multiple important advantages over 
traditional allogeneic HCT including but not limited to reduced risks of life-
threatening complications such as graft vs. host disease (Ballen, Gluckman, & 
Broxmeyer, 2013; Mayani, Wagner, & Broxmeyer, 2020).  Unfortunately, one of 
the major impediments hindering advancements of the field is the insufficient 
number of functional and immune-compatible HSCs for larger pediatric and adult 
patients (Ballen et al., 2013; Mayani et al., 2020; Talib & Shepard, 2020). Efforts 
to increase the number of engrafting HSCs are crucial for better clinical 
outcomes. For this reason, a reliable phenotyping marker for HSCs for ex vivo 
expansion that is well-correlated with their engrafting function in vivo is practically 
needed. 
 
Consistent with others’ findings, I did not find any phenotypic changes in murine 
BM hematopoietic compositions of germ-line Lepr-/- mice as compared to WT. 
Our data demonstrated that LEPR+LSK cells although representing a much 
smaller percentage compared to LEPR-LSK cells, were significantly enriched with 
higher numbers of long-term CRUs, as demonstrated in limiting dilution assay, 
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and possessed extensive and robust self-renewal capacity in secondary 
transplants. Importantly, further functional characterizations revealed LEPR 
differentiating SLAM HSCs (LSKCD150+CD48-) into two functionally distinct 
populations of HSCs. LEPR+ SLAM HSCs being a very minor subset of total 
SLAM HSCs in the mouse BM, exhibited significantly higher repopulating 
potential and self-renewing capacity in comparison to LEPR- SLAM HSCs. To 
gain insight into the transcriptomic regulations that may be responsible for the 
functional properties of LEPR-expressing stem and progenitor cells, bulk-RNA 
seq was performed and showed that mouse BM LEPR+ SLAM HSCs were 
characterized by a unique molecular network - a proinflammatory transcriptomic 
profile and pathways that are crucial for embryonic HSC development. Our data 
thus suggested that LEPR+HSCs represent a small but highly potent subset of 
adult HSCs that retained an embryonic-like molecular signature with robust long-
term primary and secondary repopulating potential. Considering the current 
knowledge that phenotype may not recapitulate function for HSCs (Chen et al., 
2019), our work helps to identify a reliable marker for highly repopulating and 
self-renewing long-term adult BM HSCs. Though still preliminary and limited in 
scope, our extended data in older mice revealed that as mice aged (even as 
young as 13 – 16 months old or middle-age) fractions of LEPR-expressing HSCs 




Consistent with mouse data, our studies of LEPR in human umbilical cord blood 
CD34+ cells illustrated that only a small portion of hCB CD34+ cells expressed 
LEPR. In a similar comparison to murine LEPR+LSK cells, LEPR+CD34+ cells 
were highly enriched for phenotypically-defined human HSCs, and functionally 
they engrafted better than LEPR-CD34+ cells in a limiting dilution assay 
transplant. Although the human engraftment studies did not meet statistical 
significance, because leptin and leptin receptor are highly conserved between 
mouse and human, our findings may have implications for the fields of both adult 

















Table 4.1 Summary of major findings (Trinh et al., 2020) 
Mouse • Only a very small percentage of BM hematopoietic cells 
express LEPR 
• Within different LEPR-expressing hematopoietic populations, 
fractions of LEPR+ stem cells are significantly higher than 
LEPR+ progenitor cells 
• LEPR+LSK cells are significantly enriched for phenotypically 
defined HSCs, MPPs and contain higher absolute numbers of 
colony-forming progenitor cells and self-renewal CRUs 
• LEPR+ SLAM HSCs engraft better and contain significantly 
more CRUs than LEPR-SLAM HSCs  
• LEPR+HSCs share similar homing capacity, lineage output 
and cycling status with LEPR-HSCs 
• Molecularly, LEPR+HSCs are characterized by a 
proinflammatory transcriptome and more highly enriched for 
genes associated with LT-HSCs, whereas LEPR-HSCs are 
more highly enriched for progenitor-associated gene sets 
• As mice age, percentages of LEPR+HSCs significantly 
expanded as compared to LEPR+HSCs  
hCB   • LEPR+CD34+ cells represent a small subset out of total CD34+ 
cells  
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• LEPR+CD34+ cells show a trend toward enhanced 






















Beyond the scope of our study, the presence of LEPR in human leukemia cell 
lines and primary patient samples is repeatedly reported in the literature (Gorska 
et al., 2013; Konopleva et al., 1999; Z. Lu et al., 2017; Nakao et al., 1998; Ozturk 
et al., 2012). A recent study (Z. Lu et al., 2017) demonstrated that LEPR 
signaling mediated the protective effects of fasting on acute lymphoblastic 
leukemia (ALL), but not AML, cells. The study provided therapeutically relevant 
mechanisms. Using the activated Notch1 T-ALL model, the N-Myc B-ALL model 
and the MLL-AF9 AML model, it was found that fasting significantly suppressed 
ALL, but not AML, development by promoting blast cell differentiation and hence 
prolonged leukemia-induced mouse survival. RNA-seq analyses of leukemic B-
ALL cells revealed expression levels of multiple cytokine receptors upregulated 
by fasting including Lepr and its major downstream effector, the transcription 
factor STAT3. This study (Z. Lu et al., 2017) also pointed out that expression of 
LEPR was positively correlated to survival rates in patients with pre-B-ALL. It was 
confirmed that B-ALL, T-ALL and AML leukemic cells express the long isoform 
OB-Rb; likewise, fasting did not upregulate Lepr in AML as it did in B-ALL and T-
ALL cells. To investigate potential role(s) that LEPR signaling plays in ALL 
development, WT mice were transplanted with N-Myc-infected BM Lin- cells that 
either came from WT (Lepr+/+) or Lepr-/- (db/db) mice. Recipient mice that 
received Lepr-/- leukemia-transformed BM cells developed B-ALL at a 
significantly faster rate, had higher multi-organ leukemic burden and lower 
survival rate. The Lepr-/- group had a higher percentage of B220+CD43+ 
precursors and a lower percentage of differentiated B220+IgM+ cells, which 
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suggested that LEPR signaling was critical for the differentiation of B-ALL cells. 
Similar results were observed in T-ALL but not in AML models (Z. Lu et al., 
2017). Furthermore, the investigators repeated these experiments, but recipient 
mice were fasted for 48 h upon attaining about 60% of leukemic-transformed 
GFP+ cells in PB. Consistent with initial findings, fasting attenuated percentages 
of GFP+ leukemic cells and increased percentages of differentiated IgM+ cells in 
the WT (Lepr+/+), but not in Lepr-/-, group. This confirmed that the anti-leukemic 
effects of fasting were mediated through LEPR signaling (Z. Lu et al., 2017).  
 
Mechanistically, LEPR overexpression in B-ALL cells led to upregulation of key 
transcription factors in B cell terminal differentiation including Xbp1 and Prdm1 
(Z. Lu et al., 2017). Overexpression of Prdm1 blocked B-ALL development, and 
knockdown of Prdm1 inhibited the anti-leukemic effect of LEPR overexpression 
in B-ALL. In silico analyses of patient databases showed that LEPR signaling and 
its related genes were positively correlated with better outcome and survival in 
pre-B-ALL leukemia. It was also demonstrated that fasting negatively regulated 
B-ALL development in a xenograft model transplanted with human pre-B-ALL cell 
line NALM-6, and it did so by upregulating LEPR expression (Z. Lu et al., 2017).  
 
A Lep-/- mouse model (Ob/Ob) was used to investigate potential effects of obesity 
on development of AML from myeloid dysplastic syndrome (MDS) and its 
associated mortality rate (Kraakman et al., 2018). Using BM from NUP98-
HOXD13 transgenic mice, a model of MDS, compared to lean WT controls, 
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obese Lep-/- recipient mice had significantly higher survival rates, and opposite to 
the researchers’ hypothesis these mice did not have increased risk of AML 
transformation. While Lep-/- recipient mice transplanted with NUP98-HOXD13 BM 
had more severe monocytosis, it was suggested that their expanded adipose 
tissue was capable of harboring more myeloid cells, and hence reduced their 
detrimental accumulation in other vital organs such as the liver (Kraakman et al., 
2018). Even though the authors rationalized their reasons for excluding the 
potential effects of Lep knockout on their findings, it would have been of more 
interest if the phenotypes were consistent in a different model of obesity and 
NUP98-HOXD13 induced MDS. Furthermore, considering that obese individuals 
are at higher risk for leukemia development and obese children afflicted with 
leukemia have increased mortality rate (Ladas et al., 2016; X. Ma et al., 2009; 
Murphy et al., 2013; Weiss, Vogl, Berger, Stadtmauer, & Lazarus, 2013), this 
study posed discrepancies between mice and humans, and thus requires future 
in-depth reevaluation. 
 
In addition to being present on leukemic hematopoietic lineage cells, LEPR-
expressing stromal cells have also been demonstrated to be involved in BM 
fibrosis of primary myelofibrosis (PMF), a subtype of myeloproliferative 
neoplasms (Decker et al., 2017). While LEPR+ mesenchymal stromal cells have 
been studied more extensively in normal hematopoiesis, the malignancy 
transformation potential of these prominent niche cells is far less understood. It 
was demonstrated that these cells were functionally and molecularly altered 
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during the progression of thrombopoietin (TPO)-overexpressing-induced PMF 
(Decker et al., 2017). Specifically, by using different genetic fate mapping models 
it was discovered that as the mice developed PMF, LEPR+ stromal cells 
significantly expanded in numbers and increased production of collagen, which 
led to BM hematopoietic failure, fibrosis and extramedullary hematopoiesis. In 
line with this finding, gene expression analyses demonstrated that LEPR+ stromal 
cells down-regulated HSC supporting growth factors including Cxcl12 and Scf 
while up-regulating genes involved in fibrotic conversion. Importantly, 
mechanistic studies pinpointed platelet-derived growth factor receptor alpha 
(PDGFRα) as the key player in the pathogenesis of bone marrow fibrosis caused 
by LEPR+ stromal cells. This was therapeutically relevant since imatinib, an 
inhibitor of different tyrokine kinases including PDGFRα, was shown to lessen 
fibrosis in this model of PMF (Decker et al., 2017). Even though the study 
focused on PMF, it has opened up a new area for future studies into  
microenvironmental niche cells in other hematological malignancies, which is 
arguably just as important as studying the leukemic cells themselves.  
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Figure 4.1  




Figure 4.1 LEPR+HSCs under steady state condition becomes ‘activated’ in 
post-injury recovery (hypothetical). 
A. Under homeostasis LEPR+ HSCs only express short isoforms of Lepr 
(OB-Ra & OB-Rc) and are characterized by a proinflammatory 
transcriptomic profile. 
B.  Hypothetically, LEPR+HSCs may express long isoform of Lepr (OB-Rb) as 




















4.2 Future directions  
4.2.1 Role(s) of LEP/LEPR in hematopoiesis under non-pathological 
conditions 
While our work suggested that LEPR can be used as a surface marker for 
functional long-term hematopoietic stem cells, it does not entirely rule out the 
possibility that LEPR could be a functional receptor under other different 
circumstances. Similarly, regarding the extensive findings on the multifunctional 
importance of LEPR-expressing BM niche cells for adult hematopoiesis, it would 
also be meaningful and clinically relevant to know whether the LEP ligand itself 
mediated these effects or if there were alternative cytokine cross-signaling 
pathways that acted through LEPR, for example like IL-6 signaling (Baumann et 
al., 1996; Sadagurski et al., 2010). Furthermore, leptin has been reported to have 
a putative truncated site for DPP4 (O'Leary, Ou, & Broxmeyer, 2013); hence, if 
LEP turns out to induce signaling on HSCs/HPCs and/or stromal cells it will be 
worthwhile to determine how the truncated version of leptin might alter leptin’s 
functions on those cells.  
 
Though we did not observe a bias in fate decision in young adult BM 
LEPR+HSCs, it is important to determine whether this will hold true as the 
organism ages. Our phenotyping data in middle-aged suggested that aging 
affected phenotypic LEPR+HSCs and multiple lineage-biased subsets of 
LEPR+MPPs to a greater extent than it does on LEPR- cells. Hence, it will be 




by performing in vitro CFU assay and in vivo quantitative competitive 
transplantation assays on a cell-to-cell basis.  
 
On the other hand, based on our evidence that LEPR+HSCs carry an embryonic-
like transcriptomic profile and the fact that leptin plays a role in endothelial cell 
functions and angiogenesis (Park et al., 2001; Sierra-Honigmann et al., 1998), a 
critical question remaining is whether LEPR/LEPR signaling has any effects 
during the emergence of HSCs from the hemogenic endothelium. Would it be 
possible that the functional isoform Ob-Rb of Lepr got turned off once HSCs 
successfully emerged from embryonic endothelial cells? All of these warrant 
future in-depth studies as the answers to those questions might have potential 
implications both for the field of hematological malignancy research and HSC 
transplantation.  
 
4.2.2 Role(s) of LEP/LEPR in hematopoiesis under pathological/leukemic 
conditions 
For future work, it will be interesting and relevant to investigate further functional 
characteristics of stem cells with disrupted LEP/LEPR signaling. For instance, 
how would it affect the ability of the cells to differentiate versus maintaining a 
stem-like state? Would it affect one or multiple lineages and to which extent? 
Would the effect(s) be reversible? Would the effect(s) be similar under steady 





Given our findings in the present study, it could be logically inferred that LEPR-
expressing leukemia blast cells might possess potent stemness, enriched for 
leukemia-initiating cells and hence more likely to be resistant to radiation and 
chemotherapeutic regimen. Since aging is associated with increased risks for 
malignancies particularly myeloid-biased leukemia, and LEPR-expressing 
HSCs/HPCs expanded phenotypically in older mice, it is clinically relevant to 
investigate more into their molecular mechanisms such as increased cell 
proliferation leading to functional exhaustion and higher risk for leukemic 
transformations. It will also be helpful to characterize their genetic and epigenetic 
programs under aged conditions, which can provide more insights into normal 
and abnormal stem cell aging.  
 
In addition, provided that LEPR+HSCs engrafted significantly better than LEPR- 
cells upon irradiation and their highly proinflammatory transcriptome, it may be 
worthy to determine if LEPR+HSCs are transcriptomically equipped under steady-
state to respond to acute injury at a higher efficiency and faster rate. This could 
also be extrapolated into other situations such as in emergency hematopoiesis 
(e.g. acute infection) or even chronic infection in which the cells are constantly 
exposed to low-grade proinflammatory microenvironments. It is important to 
elucidate whether in such circumstances as leptin has any direct effects on HSCs 
and/or indirect effects through the BM niche, or perhaps a central vs. peripheral 




of LEP/LEPR in hematopoiesis under normal and pathological conditions is 





























o Molecular mechanisms by which LEPR signaling 
in stromal cells regulate expression of important 
niche factors under steady state vs. post-injury 
hematopoietic regeneration. 
o Is LEPR on HSCs just a surface marker or is 
LEPR functional especially in context of post-
injury recovery?  
o Does the sources of LEP (e.g. systemic vs. local 
BM adipocytes) matter?  
o Does LEP/LEPR play any roles in the 
specification of HSCs during embryonic period 
up until birth? And if so, by which mechanisms? 
And how does maternal and fetal leptin 
production affect these processes? 
o How may aging exert differential effects on 
LEPR+ stromal cells or LEPR+ HSCs vs. LEPR- 
cells?  
o Does LEP signal through other cytokine 
receptor(s) in the same family that may be 







o Do LEPR+ HSCs/HPCs possess different 
potentials for leukemic transformation from 
LEPR- cells? How can other risk factors possibly 
further modulate the difference? 
o There were discrepancies between MDS model 
using Lep-/- mice and patient studies. Was this 
actually due to obesity alone as suggested or 
the absence of LEP played additional roles? 
o While healthy mouse HSCs/MPPs were 
reported to express predominantly only the short 
isoforms under steady state, by which 
mechanisms the leukemic blast cells for both 
myeloid and lymphoid malignancies reactivated 
LEPR long isoform? And how does this affect 













LEP and LEPR signaling play important modulatory roles throughout an 
organism’s life from conception to old age. LEPR resistance is well-recognized in 
obesity and aging (Myers et al., 2010; Sasaki, 2015). With a persistently 
increased prevalence of obesity and growth in the elderly populations worldwide, 
understanding how the different pathological conditions including hematologic 
malignancies and hematopoietic transplantation-associated complications 
biasedly affected these subsets of patients has become even more important. In 
this report, we noted and highlighted the work that provided proof-of-principle 
evidence for more future in-depth studies. A summary of what is known about 
LEP and LEPR in hematopoiesis can be found in Table 1.1. In brief, LEP/LEPR 
have been suggested to regulate stem cell numbers and functions particularly in 
the hematopoietic system under homeostasis, as well as post-injury regeneration 
and malignant transformation. Even though there are still some discrepancies 
between different studies or between animal and human data especially 
regarding LEPR and leukemic cells, the findings lay a strong foundation and 
create interesting questions to be answered in follow-up studies. Future work that 
elucidates and provides insight into mechanisms of LEP/LEPR interactions is 
warranted and may provide potential implications for therapeutic approaches to 
enhance healthcare.  
 
 








Graphical Abstract  
 
• Under steady state, only a minor subset of long-term hematopoietic stem 
cells (HSCs) express LEPR 
• Upon irradiation, LEPR+HSCs exhibited robust repopulating capacity in 
long-term engraftment studies that outcompeted LEPR-HSCs 
• LEPR+ stromal cells secrete critical niche factors including stem cell factor 
(SCF) and pleiotrophin (PTN) to support HSCs and progenitor cells 
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of unbiotinylated-ENO1 peptide using 




Western blot, recombinant DNA techniques 
(digestion and ligation of DNA, cell 
transformation, colony PCR, etc), mammalian 
cell culture, DNA and protein extraction and 
purification, real-time polymerase chain 
reaction, ENO1-activity assay. 
 
06/2012-05/2014  Work in Dr. Premaraj’s Lab (3 – 6 hrs/week) 
    Department of Growth and Development  
    University of Nebraska Medical Center, College of 
Dentistry 
• Techniques performed:  Extract DNA from 
bacteria collected from patients’ samples, 
mammalian cell culture maintenance. 
 
05/2013-08/2013  Summer Research Internship in Dr. Crawford’s Lab 
(40 hrs/week) 
    Department of Cancer Biology 
    Mayo Clinic Cancer Center 
• Project: “Transactivation of EGF receptor 





• Techniques performed: Pancreatic acinar 
cell preparation, BCA protein concentration, 
Western Blot. 
 
Fall 2010   Research in Dr. Grass’ Lab (7 hrs/week) 
    Department of Biochemistry 
    University of Nebraska, Lincoln, NE 
• Help maintain lab’s biochemical solutions 
for bacterial culture 
• Initiated a project on the effects of metallic 
copper surfaces on the survival rate of 
Escherichia coli and Staphylococcus   
• Technique performed: bacterial cell culture, 
bacterial cell lyses. 
 
Extracurricular Activities 
10/2020 – present Nguyen Hien Le Scholarship Foundation (English 
education program for outstanding students from disadvantaged background in 
Vietnam) 
2017 – 2020  Shadowing, Good Samaritan Free Health Clinic (once 
a month) 
2017-2018                           Mentor for the Undergraduate Mentorship Program 




04/2017  Director of Faculty Outreach for Evening of the Art, 
IUSM 
05/2011-05/2014  Volunteer, Vietnamese Buddhist Temple (1 hr/week) 
Fall 2013   Human physiology teaching assistant (1 hr/week) 
08/2013   Clinic with a heart (on-call Vietnamese interpreter) 
08/2012-05/2013  Service Chair, Phi Upsilon Omicron  
07/2012-05/2013  Volunteer, Bryan LGH Medical Center (2hrs/week) 
08/2011-09/2012  Academic tutor, WHT Learning Community 
04/2008 – 08/2012  Sales clerk in Chinese Food, Hy-Vee Grocery Store, 
Lincoln, NE 
08/2009 – 12/2011  Volunteer, People’s Health Center (2 hrs/week)  
Fall 2011   Volunteer tutor, Education Talent Search, UNL (2 
hrs/week) 
Fall 2010 Volunteer, Lincoln International Networking 
Community (6 hrs/month) 
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